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Abstract
Pyrrole-imidazole polyamides (PAs) are small molecules that typically develop
H-bonds to bind to the minor groove of DNA. PAs are of interest because they can be
designed to recognize DNA sequences. PAs have numerous biomedical applications in
areas like regulation of gene expression and antimicrobial activity. Specifically,
polyamide UMSL1011 (a polyamide synthesized in Dr. Bashkin's lab) inhibits
replicating vesicular stomatitis virus (VSV) by binding the viral RNA inside the
nucleocapsid, as indicated by research at Professor Ming Luo's lab at Georgia State
University. However, some reports have revealed that polyamides have a low affinity for
“simple” double-stranded RNA. Nevertheless, those reports became insignificant after
our joint report of the crystal structure of UMSL1011 binding RNA inside a VSV
nucleocapsid-like particle, where the polyamide makes strong contacts with both RNA
and protein.
Our goal was to synthesize new PA molecules based on the active shape of
UMSL1011 in the crystal structure, which is unlike that of any previously characterized
polyamide (for example, the rings of UMSL1011 are not π-stacked when bound to the
VSV nucleocapsid and genomic RNA, but they are π-stacked in other known structures).
We used the information‐rich crystal structure to help design these new PAs and
submitted the compounds for additional cell culture testing against VSV, eventually
hoping to test the most active compounds against the respiratory syncytial virus, RSV.
We chose VSV as an initial experimental virus because VSV does not kill cells as
quickly as the clinical target RSV, presenting a better opportunity to measure antiviral
candidates' protection.

i

The first part of this report describes building a molecule that mimics the
truncated portion of UMSL1011. The building blocks were linked to β-alanine PAM
resin via solid-phase methods. Cleavage of the compound from PAM resin under mild
conditions was essential to maintain the compound's stability. The second part of this
report focuses on building several short-long polyamide chains with remarkable
modification by substituting three N-terminus groups on either pyrrole or imidazole
moieties to enforce the binding with genomic RNA.
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Chapter 1
Introduction

1

1.1 N-Methylpyrrole/ N-Methylimidazole Hairpin Polyamides (PAs)
1.1.1 Story of Pyrrole-Imidazole Polyamides
Designing small molecules to target predetermined DNA sequences is an
important goal to regulate gene expression and develop a therapy for human diseases,
including cancer and infection, with limited toxicity.1
Pyrrole-imidazole polyamides comprise small aromatic amino acids linked
through amide bonds that selectively bind to DNA molecules' minor groove.2 This class
of cell-permeable compounds can bind to ds-DNA's minor groove in a sequence-selective
fashion without causing DNA denaturation (in fact, the DNA duplex is stabilized by
polyamide binding).3-4 Pyrrole-imidazole polyamides were developed based on natural
DNA minor groove binding agents netropsin and distamycin A.5 Netropsin and
distamycin A contains two or three pyrrole moieties, respectively (Figure 1.1).

1

2

Figure 1.1. Chemical structure of netropsin and distamycin A. The image adapted
from Yusuke, et al. 2018 (permission # 5007241008789).

2

Distamycin, which targets a relatively narrow DNA minor groove, was found to
widen that groove and formed both 1:1 and 2:1 ligand- DNA complexes into A/T rich BDNA.

6-7

Netropsin would instead bind only to the minor groove of A/T- rich double-

stranded B-DNA with a 1:1 stoichiometry.8
The cationic guanidinium moiety at the N-terminus of netropsin (shown at the Nterminus of 1 in Figure 1.1) improves both the solubility and the affinity of netropsin
with anionic DNA sequences. However, cationic groups at both ends of netropsin prevent
stacking of netropsin molecules in the minor groove because of charge-charge repulsion.9
The crescent shape of netropsin can fit with the inherent curvature of the minor groove of
B-DNA, allowing appropriate van der Waals and hydrogen bond interactions.8
Dickerson and his team predicted that replacing the pyrrole ring with the
imidazole ring permit recognition of G/C base pairs based on structural analysis and form
a hydrogen bond between the exocyclic amino group on guanine and N3 on imidazole
and.8 The pioneering work from the Dickerson, Lown, and Dervan groups paved the way
to investigate that the trimer of Im-Py-Py-Dp, a netropsin analog, can recognize and bind
to 5--TGTCA-3 as a 2:1 ligand–DNA complex (Figure 1.2).10-11
The polyamide binds the minor groove of DNA, usually with the N- to Cterminus aligned in the 5' –3' direction and forms an antiparallel homodimer fashion.
Sometimes, polyamides align in a 3’-5' direction or so-called reverse orientation.12 It is
possible to program small PAs to bind specific DNA sequences with affinity and
selectivity similar to naturally occurring DNA-binding proteins using the side-by-side
pairing of the aromatic amino acids. Studies have demonstrated the DNA recognition
rules by precisely oriented pyrrole pairs and imidazoles linked by amide bonds. The

3

Py/Py pairs bind with A·T and T·A base pairs, the Im/Py pair recognizes G/C base pairs,
and Py/Im recognizes the C/G base pair (Figure 1.2).10-11

Figure 1.2. Recognition of the minor groove of ds-DNA via netropsin
derivative. The image adapted from Yusuke, et al. 2018 (permission #
5007241008789).

However, this specificity of PA-DNA recognition does not apply to long antiviral
polyamides, whose binding is governed by entropy rather than enthalpy, as our group has
recently shown with Dr. Dupureur.13-14
1.1.2 Structure and Pairing Rule of Hairpin Py-Im Polyamides
The short linear of Py-Im polyamide, as we mentioned in the previous section, can
form homo and heterodimers into the minor groove of ds-DNA.11
Hairpin polyamides have been developed based on this finding, in which two linear
oligomers can connect via an alkyl linker.15-18
4

Compared with an unlinked parent, linear polyamides, hairpin polyamides for
matching sequences can have a stronger affinity and greater specificity.19 Dervan and
coworkers have reported the first novel of hairpin polyamide to increase the variety of
covalent of Py-Im dimeric polyamides, where the C-terminus of one motif and the Nterminus of another polyamide were covalently connected by γ-aminobutyric acid (a socalled γ-turn) (Figure 1.3).20

Figure 1.3. recognition sites in the minor groove of ds-DNA by hairpin polyamide. Ƴ-turn
binds A/T or T/A base pairs, Py/Im binds C/G base pair, Py/Py binds A/T or T/A base pairs,
Im/Py binds G/C base pair, Ƴ-turn binds A/T or T/A base pairs, and β-Ala tail binds A/T or
T/A base pairs. The image adapted from Yusuke, et al. 2018 (permission # 5007241008789).

Yusuke and coworkers reported that the interaction between pyrrole-imidazole
moieties and nitrogenous bases occurred via hydrogen bonding interactions (Figure 1.4).21
On the other hand, the substituted (γ-turn) moiety can enhance the binding affinity and
5

specificity while maintaining or enhancing the binding orientation of polyamide.11 One of
the features of synthetic building block γ-aminobutyric acid (γ) is that the (γ) linker causes
molecules to develop the shape of a hairpin motif. These hairpin ligands bind to limited
target sites with more than 100 times higher affinity relative to paired polyamide
monomers.9

Figure 1.4. The hydrogen bond interaction between bases and Py, Im, or Hp residues.
Pyrrole binds adinine, thymine, and cytosine through hydrogen bonds between NH on
pyrrole with N3 on adinie, the O2 on thymine, and the O2 on cytosine, imidazole binds
guanine only through hydrogen bond between NH group on imidazole with both N2 and N3
on guanine, Hp binds thymine through hydrogen bond between O2 on thymine with both
hydrogens on O and N respectively. The image adapted from Yusuke, et al. 2018 (permission
# 5007241008789).

Compared to traditional PAs, hairpin PAs have the advantage of forming a 1:1,
side-by-side complex with the two strands of DNA minor groove, usually with higher
affinity and specificity.22 However, challenges occur in designing elongated PAs
structure to recognize DNA, let alone RNA, for which rules are not established.
Moreover, lengthening hairpin PAs to eight or more rings leads to an over-curved
structure that no longer resembles the minor groove shape of B-form DNA. The resulting
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shape mismatch for long PAs leads to a loss of hydrogen bonding strength, decreasing
binding affinity, and specificity.23-24
In 1999, Swalley and coworkers reported that inserted β-alanine at the Cterminus could enhance the binding affinity and specificity of polyamide and recognize
either A/T or T/A base pairs (Figure 1.3).25 Furthermore, substituted β-alanine within
hairpin polyamide could work as a spring that relaxes polyamide's curvature, resulting in
efficient binding.26
1.1.3 Pyrrole-Imidazole Polyamides Applications
Pyrrole-imidazole polyamides have binding affinities similar or better to those of
transcription factors. They are often cell-permeable, localizing to the nucleus in living
cells without requiring any delivery agent.27 Based on this fact, many attempts have been
made to regulate gene expression in living cells via disturbing the DNA-transcription
factor interaction using polyamides. In this chapter, we present some reports exploring
the application of polyamides as gene expression modulators.28-29
Gottesfeld and his team in 1997 reported that an eight-ring hairpin polyamide
could target a specific region of the transcription factor TFIIIA binding site within the
intragenic promoter element of the Xenopus 5S RNA gene in cultured Xenopus cells.30
Jansen and his team synthesized different chains of polyamides for targeting different
Drosophila melanogaster satellites, including AT-rich satellites I, III, and SARs (scaffold
associated regions), and induced specific gain- and loss-of-function phenotypes.31
Some factors, such as vascular endothelial growth factor (VEGF) and its
receptors, can display an essential role in tumor angiogenesis and are upregulated by
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hypoxia. Designed hairpin polyamides were found to silence the binding of hypoxiainducible factor (HIF) to HRE in HeLa cells by binding the hypoxia-response element,
resulting in a reduction in the number of hypoxia-inducible genes and the expression of
VEGF.32 Further studies demonstrated that polyamides target the expression of
proangiogenic and premetastatic factors using a tumor xenograft model, resulting in
inhibiting the formation of new tumor blood and suppressing tumor growth.33
Hochhauser and his team designed a polyamide (JH-37) to block the repressive
binding of the transcription factor NFY within the Topoisomerase IIα (Topo IIα)
promoter.34
Hairpin PAs can also be used as artificial transcriptional activators.31 Kodadek
and coworkers in 2007 reported that a cell-permeable synthetic polyamide could activate
the transcription of a reporter gene in HeLa cells.31 The polyamide was linked to a
derivative of a coactivator-binding peptoid (oligo-N-substituted glycine) isolated from a
combinatorial library.35 Furthermore, pyrrole-imidazole polyamides can be used to detect
specific sequences, discriminate mismatched sequences, and investigate the localization
of polyamides by conjugated to imaging agents such as fluorescent compounds.36
Laemmli and coworkers in 2001 used Texas Red-labeled tandem hairpin Py–Im
polyamides to target a specific visualization of insect (5 -(TTAGG)n -3 repeats) and
vertebrate (5 -(TTAGGG)n -3 repeats) telomeres in fixed, permeabilized cells and in
chromosomal cell spreads.37
However, our lab reported studies on large polyamides with anti-HPV (human
papillomavirus) activity in epithelial cell and tissue cultures, without evidence of
cytotoxicity up to their solubility limit (150-200 μM).38 The pyrrole-imidazole
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polyamides are known as ds-DNA minor groove binders; they enter the HPV-infected
cells and are shown to trigger the degradation and elimination of HPV DNA. The binding
with these molecules might induce a structural alteration in the viral DNA and elicit the
DNA damage response (DDR) pathway.39 In 2018, Bashkin and his coworkers reported
polyamide's antiviral activity against two types of polyomavirus family, Simian virus 40
(SV40) and BK virus, thus expanding the spectrum of activity of other double-stranded
small DNA tumor viruses.40 Nowadays, a library of more than 100 polyamides includes
PAs that differ in length, building-block sequence, C-terminal tail, and N-terminal
substitution, has been built.41
1.1.4 Pyrrole-Imidazole Polyamides as a Potential Antiviral Drugs Against negativestrand RNA Viruses (NSVs)
Negative-strand RNA viruses are enveloped viruses with a single RNA molecule of
negative-sense that can cause several life-threatening diseases, such as respiratory
syncytial virus, vesicular stomatitis virus, and Ebola virus.42 All viruses have a common
feature, such as assemble a nucleocapsid. Nucleocapsid N is a particle containing a
protein coat and a single-strand RNA genome. The term capsid refers to the protein shell
that surrounds the genome of the viral particle. The primary role of this capsid is carrying
and protecting the viral genome during transmission between cells.43-45
There are many similarities in VSV and RSV's lifecycles, such as they can encode
their RNA-dependent RNA polymerase (vRdRp) in the genome. Moreover, the genomic
RNA encapsidated in the nucleocapsid for RSV and VSV can form a structure
resembling one strand of an A-form RNA duplex.42, 46
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Various polyamides have proved potent activity against papillomaviruses and
polyomaviruses by decreasing viral DNA concentration from 50-90% in cell culture.47-48
However, binding to RNA has had mixed success because reports have shown that these
polyamides do not bind well to RNA.49-50 We decided not to be deterred by studies
involving conventional, single-stranded RNA because many important biological RNA
molecules are highly structured and began working on RNA viruses with collaborator
Ming Luo of Georgia State University. Recently, a report from this collaboration showed
that a polyamide we supplied UMSL1011 could target viral RNA in the nucleocapsid and
inhibit replication of the negative-strand RNA virus, vesicular stomatitis virus, or VSV.51
Vesicular stomatitis virus VSV has been chosen as a preliminary model for testing
polyamide's binding before looking for anti-RSV effects because its virology is similar to
that of a respiratory syncytial virus or RSV.51 UMSL1011 was found to inhibit
replication of VSV, allowing cells to remain alive after infection with this lytic virus.51
1.2 Respiratory Syncytial Virus Infection
1.2.1 Classification
Respiratory syncytial virus RSV is a pathogenic virus that can infect infants,
young children, the elderly, and the immunocompromised. This serious virus belongs to
the Paramyxoviridae family and causes severe respiratory infections throughout life.52
RSV is an enveloped virus (80–350 nm in diameter), pleomorphic, and a Pneumovirus
genus member.53 RSV was first isolated as an agent causing coryza in chimpanzees in
early 1956; soon afterward, it was isolated from children with pneumonia and
bronchiolitis and became globally known as a severe acute lower respiratory tract
infectious disease.54 Furthermore, more than 30 million new episodes of acute lower
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respiratory tract infections in children under five years occurred from RSV in 2005, with
severe cases requiring hospitalization.55
Moreover, fifty thousand deaths of children under five years of age annually are
attributed to RSV by global estimates of the disease burden.56 Not only young children
infected by this virus but also the elderly and immunocompromised are also at an
increased risk for severe disease with RSV.57 To date, RSV isolates can be classified into
two subgroups, A and B, segregated into virus lineages or clades, and exhibiting
antigenic and genetic differences. The surface G glycoprotein of prototype A and B
viruses shows considerable ectodomain divergence, with only 53% amino acid identity.58
1.2.2 Genome Organization and Viral Proteins
RSV is a single-strand negative-sense RNA genome with approximately 15 kb
and an enveloped structure mentioned earlier. Its genome encodes 11 proteins: the
nucleocapsid-associated proteins (M2-1, P, L), an M2-2 protein (the second ORF of the
M2 gene), the nucleocapsid protein (N), one matrix protein (M), three transmembrane
proteins (F,
G, SH), and two non-structural proteins (NS1, NS2) (Figure 1.5).59-60
The nucleocapsid contains both the viral RNA genome and the nuclear protein N.
Binding N protein to P protein may prevent the nonspecific binding to cellular RNAs
before nucleocapsid assembly.61 Encapsulating genomic RNA to N protein,
phosphoprotein P, and RNA- dependent RNA polymerase L leads to forming a helical
ribonucleoprotein (RNP) complex and then protecting the RNA and forming the minimal
replication machinery.60 The L protein plays an essential role in replicating the viral RNA
genome, transcribing mRNAs, capping enzymes, and methylating the mRNA cap.62
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Moreover, engaging L protein with promoter sequences that lie at the 3′ ends of the
genome and antigenome RNAs can perform genome transcription and replication.63
The phosphoprotein P can form homotetramers by binding to L, N, and M2-1.60.
The M2-2 protein can regulate the switch between the viral RNA transcription and
replication process since it dispensable for RSV replication.61 The M2-1 protein can
contribute to RNA transcription, elongation, and switching RNA synthesis from protein
transcription to genome replication.59 The M protein can inhibit viral transcription via
forming a bridge between the viral RNP and envelope.46 On the other hand, RSV contains
three membrane proteins: small hydrophobic protein SH, glycoprotein G, and fusion
protein F.46 The role of SH protein is not understood yet since it not necessary in virus
binding.46 The other two proteins, G and F, are serving as viral attachment proteins.63 The
two RSV non-structural proteins, NS1 and NS2, resist the cellular antiviral response and
induce interferon (IFN) signaling.59

Figure 1.5. Type of Encapsitated Proteins inside RSV Molecule. Single-stranded negativesense RNA genome consisting of 11 genes (NS1, NS2, N, P, M, SH, G, F, L, M2-2, M2-1).
European Respiratory Scociety ERS hereby grants you permission to reproduce the material
as requested for your thesis (print and digital) and full acknowledgement must be given.
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1.2.3 RSV Replication
The infection is initiated when the virus attached to the host cell surface via
electrostatic interaction between the heparin-binding domains on the G glycoprotein and
the cell-surface
glycosaminoglycans.64
Binding RSV F glycoprotein to nucleolin on the cell surface triggers a
conformational change in the protein, causing membrane fusion and RSV particles' entry
(Figure 1.6).65

Figure 1.6. RSV Life Cycle. All our journals are open access
(http://about.hindawi.com/auhors/open-acess/), including Advance in Virology. All articles
are puplished under the creative common’s attribution license (http://creative
commons.org/license/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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The nucleocapsid containing the viral genome, N, L, P, and M2-1 proteins, will
release into the cytoplasm, causing genome transcription and replication via L protein.65
Following genome transcription and replication, transcription of the viral mRNA can
occur via promoter nearby the 3՜ end, leading to a series of subgenomic mRNAs.65 At the
plasma membrane, assembly of virus can occur, and the nucleocapsids localize with the
cell-membrane containing
viral membrane glycoproteins.63
The matrix protein polymerization can affect RSV assembly and budding and
cause interaction between the G protein's N-terminal domain and the F protein's
cytoplasmic tail. As a result, new virions grow up in a cluster at the apical surface and
extend from the plasma membrane in a filamentous form associated with caveolin-1.65
1.2.4 Prevention and Therapies
For a decade, the treatment of RSV infection was a global health priority. The most
control, prevention, and treatment of RSV infection are primarily directed against two
major surface viral proteins: The G (attachment) and the F (fusion) glycoproteins.63
One of the famous antiviral monoclonal antibodies against RSV-F protein
infection is Palivizumab, also known as Synagis. This vaccine can be used for infants and
young children to prevent pneumonia caused by the RSV virus.66 The vaccine is now
licensed and regularly used to prevent severe complications from RSV infection.
However, this vaccine was not convincing enough to those considered at high risk
for severe infection, not to mention it is expensive. Moreover, more than half the world's
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population cannot access this life-saving vaccine, and it is inaccessible to children in
developing countries.67 Further, the resistance of RSV to Synagis has been reported.68
On the other hand, Ribavirin is another licensed antiviral drug available today,
widely against RSV. It can be used in oral and intravenous forms for
immunocompromised patients in high-risk individuals, particularly allogeneic stem cell
transplant recipients with severe lymphopenia.69 Nevertheless, its efficiency against RSV
is limited in otherwise healthy children and not recommended by the American Academy
of Pediatrics because some infected children developed long-term abnormalities in
pulmonary functions.70
Even though the universal public health influence of RSV is widely recognized,
no authorized vaccines nor effective drugs for acute infection currently exist except for
the drug Ribavirin, which has limited effectiveness and considerable side effects.71
Together, the incomplete coverage offered by vaccine precaution and the
absences of effective treatments emphasize the need for developing novel and more
effective therapies.
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Chapter 2
Synthesis of Novel Short Polyamide Based on The Crystal
Structure of UMSL1011, An Active Antiviral Against
VSV, Using Solid-Phase Methods
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2.1 Introduction
The remarkable feature of pyrrole-imidazole (PI) polyamides as gene-silencing
compounds has contributed widely to developing their biological application in various
scientific fields.1 The crescent shape of PI polyamides can help match the doublestranded DNA's minor groove in a nearly sequence-specific manner.2-3 Not only DNA
plays an essential role in living organisms, but RNA also widely functions in coding,
decoding, regulating, and expressing genes.4-5
The pursuit of binding polyamides to RNA was a gamble because two eminent
labs around the world reported that hairpin polyamides are incapable of binding
effectively to RNA.1,6 Some researchers have attributed the weak binding of polyamides
into double-stranded RNA to the shape of helical RNA resulting from the 2’-OH on the
ribose sugar of RNA. Compared to the DNA structure, the A-form structure of RNA has
a shallower minor groove, which leads to incompatibility with many required criteria of
hairpin polyamides. Furthermore, an overall expansion of the helix width occurs because
the base pairs of A-form RNA are inclined and displaced from the helix axis,
accompanying a shallow curvature of the A-form minor groove floor (Figure 2.1).1,7-8
However, our lab has proved those prominent labs were wrong to some extent,
partly perhaps because the RNA of single-strand RNA viruses does not form only typical
RNA helices. UMSL1011 was one member of the initial library among six compounds
sent to our collaborator, Professor Ming Luo, at Georgia State University, which
demonstrated excellent activity against vesicular stomatitis virus, VSV, a significant
success (Figure 2.2).9
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Figure 2.1. The Difference Between A and B Form for Both DNA and
RNA Molecules. The minor groove in A-form RNA is shallower than B-form
DNA while the major groove in B-form DNA is wider than A-form RNA. Figure
adapted from Stanley 2012 (permission to use #1324007665).

Figure 2.2. UMSL1011. The rings of the green portion of the molecule shows up in the
crystal structure as tightly bound to the VSV RNA nucleocapsid particle; the pink portion
is Dp; the red portion is β-Alanine; the black portion is Py that is not seen in the crystal
structure; the blue portion is dIm.
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Our collaborators, Professor Ming Luo and group, carried out the virology and
biophysics parts of this project, including crystallography. Dr. Luo reported with our
group that UMSL1011 inhibits replication in HeLa cells of the negative-strand RNA
virus VSV.
Furthermore, the action mechanism was determined to involve binding the viral
RNA and protein in the nucleocapsid particle (Figure 2.3).9 In a cellular activity assay
for viral replication, UMSL1011 successfully inhibited viral RNA synthesis, protected
HeLa cells, and acted as an active antiviral agent.9 The Luo lab also incubated a
nucleocapsid-like particle (NLP) with UMSL1011 to determine if the polyamide could
target the nucleocapsid. After treating the polyamide with NLP, they observed that the
encapsulated RNA was protected from thermo-release and digestion by a ribonuclease
enzyme.9

Figure 2.3. Crystal Structure of UMSL1011 Bound to the NLP. (A) indicates the electron
density corresponding of UMSL1011; (B) indicates that UMSL1011 forms in total seven
hydrogen bonds with RNA and two hydrogen bonds with the N protein; (C) indicates
Adaptive Poisson-Boltzmann calculations for each hydrogen bond; (D) indicates binding of
polyamide with both N protein and bases of structured RNA. ASM authorizes an advanced
degree candidate to republish the requested material in his /her doctoral thesis or dissertation.
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Moreover, some previous studies have reported that the three hydrogen atoms on
the N-methyl group, in some cases, can form hydrogen bonds with a proton acceptor
because these hydrogens are polarized.9 Therefore, the three polarized N-methyl
hydrogens of Im-4 were found to form hydrogen bonds with both the ribose and
phosphate groups between nucleotides 7 and 8.9
However, weak π-π stacking between Im-4 and the base of nucleotide 9 might
occur to reinforce Im-4 in place. Furthermore, the carbonyl group and amide nitrogen
after Py-3 can form hydrogen bonds with the bases on nucleotides 3 and 4. Similarly, a
single hydrogen bond can form between the carbonyl group directly preceding Py-6 and
amino acid Arg-312 while anchoring the γ-5 turn in otherwise undetermined space.9
Therefore, stretching UMSL1011 along with the genomic RNA and interacting with
protein can cause reliable contact among bases and the backbone (Figure 2.3 D).9-12
The most unusual feature in the crystal structure of UMSL1011 is the existing
only small visible portion of the polyamide (shown as a green portion in Figure 2.2)
whereas, the rest of the molecule has disordered. The outer section of the polyamide does
not interact in a well-defined manner with the virus particle. The crystal structure shows
that, unlike all other known hairpin polyamide structures, polyamide UMSL1011 does
not form a stacked hairpin structure with planar sections but is highly twisted and
distorted compared to previously determined structures.13 It was not previously observed
that polyamides interact with proteins; only interactions with DNA were known.14-16
Therefore, we considered newly discovered features and earlier literature to synthesize
new molecules that might match the binding site more optimally than the active
compound.
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The Luo group decided to start working on VSV rather than RSV because RSV is
so toxic to cells that it is challenging to work with unless a highly active antiviral has
been discovered. Also, RSV is a human health risk. However, there are many similarities
in the lifecycles of VSV and RSV. Therefore, the skills and techniques learned will
theoretically be transferable to work with RSV in later research. Since only the green
portion of UMSL1011 has bound tightly in the crystal structure (Figure 2.3 D),9 we
started synthesizing molecules that mimic the truncated green part of UMSL1011 to
some extent (Figure 2.4).

2

(HCO2-)2
+

H

60% isolated yield after
HPLC purification
Figure 2.4. New Designed Molecule Based on Truncated Green Portion of
UMSL1011. The new molecule consists of two five membered rings of pyrrole and one five
membered rings of imidazole; one Ƴ-turn ring; one β-alanine ring; the C-terminus group is Dp.

The goal was to make a minimal structure with the lowest possible MW that
maintained antiviral properties. We used the same building blocks as in UMSL1011 by
linking them step by step with β-alanine PAM resin via solid-phase methods. For Nprotection, Boc (tert-butyloxycarbonyl) was chosen for the exocyclic amino groups of the
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pyrrole and imidazole amino acid building blocks. A variety of short chains was
synthesized with different applied programs. Some chains had positively charged Nterminal groups; others had a neutral hydrogen-bonding N-terminal group, as described in
the next chapter.
The C-terminal group for all new candidate molecules was 3-(dimethylamino)-1propylamine (Dp) because UMSL1011 was cleaved with the same group. Therefore, the
newly designed molecules were cleaved from the resin by Dp before purification, and we
used established principles of medicinal and polyamide chemistry in their synthesis.
2.2 Methods
2.2.1 Materials & Instrumentations
Boc-beta-alanine-Pam resin was ordered from Peptides International (Louisville,
KY), 3-(dimethylamino)-1-propylamine, piperidine,

indole, ammonium

formate,

palladium hydroxide on carbon, HCl, and NaOH were purchased from Sigma Aldrich (St.
Louis, MO), methyl 1-methyl-4-nitro-1H-imidazole-2-carboxylate I was ordered from AC
Pharmachem, Inc (Worcester, MA), 4-tert-butoxycarbonylamino-1-methyl-1H-pyrrole-2carboxylic

acid

benzotriazole-1yl

ester,

HATU,

PyBOP,

4-tert-

butoxycarbonylaminobutyric acid, and trifluoroacetic acid was acquired from Oakwood
Chemical (N. Estill, SC), N, N-diisopropylethylamine, formic acid, acetic anhydride, and
Pearlman's catalyst (palladium hydroxide on carbon) were obtained from Fisher Scientific
(St. Louis, MO),). 1H and 13C NMR spectra were recorded in DMSO at 300, 600, and 151
MHz, respectively. 1H NMR is referenced to DMSO (2.5 ppm) and 13C NMR to DMSO
(39.5 ppm). Coupling constants J are reported in Hertz (Hz). The polyamides were
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synthesized using automated peptide synthesizer CS336S/CS336X. High-resolution mass
spectrometry was carried out on a JEOL MStation-JMS700 spectrometer.
2.2.2 Synthesis of NH2-Im-CO2Me
A solution of NO2-Im-CO2Me 3 (2.5 g, 13.50 mmol) and ammonium formate (3.5
g, 55.5 mmol) in ethyl acetate (20 mL) was stirred at 23 ℃ for 30 min. 1 g of Pearlman's
catalyst (palladium hydroxide on carbon) was added to the mixture, and then refluxed for
2 h. All catalysts have removed via filtration through Celite; then, the filtrate was
concentrated in vacuum to take the solvent off, then finally obtained 3 g (20 mmol, 83%
yield) of yellow-orange crude solid (Figure 2.5).17

Figure 2.5. Synthesis of NO2-Im-CO2Me.

2.2.3 Synthesis of BocPy-ImCOOH
A solution of 4 (3 g, 19.34 mmol) and 5 (3,2 g, 8.96 mmol) in DMF (20 mL) and
DIEA (3 mL, 17.4 mmol) was stirred at 23 ℃ for 8 h. Distilled H2O (30 mL) preacidified with aqueous HCl (1 N, 30 mL, 30 mmol) was added to the solution.
The solution was extracted with EtOAc (80 mL), then the organic layer was
washed with saturated NaHCO3 solution (30 mL × 3) and brine (30 mL × 2) and was
dried over anhydrous Na2SO4. Finally, the filtrate was concentrated in vacuum to give 6
(4 g, 10.6 mmol, 80% yield) as a light brown solid (Figure 2.6).17
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Figure 2.6. Synthesis of BocHN-Py-ImCO2Me.

Compound 6 (3.6 g. 9.5 mmol) was dissolved in ethanol (70 mL), then added
NaOH (1.2 g in 50 mL of water) to the solution. At room temperature, the mixture was
gently stirred overnight. After filtration, ethanol was removed by vacuum. Then HCl (6
N) was added to the remaining solution to reach PH 1. The left precipitate was washed
with water and dried after collected by filtration to afford 7 (3.2 g, 8.16 mmol, 88% yield)
as brown solid (Figure 2.7).17

Figure 2.7. Synthesis of BocHN-Py-ImCOOH.

Boc-Py-ImCOOH
1

H NMR (300 MHz, DMSO-d6)  = 12.75 (br. S., 1 H), 11.55 (s, 1 H), 9.88 (s, 1

H), 7,67 (s, 1 H), 7.54 (s, 1 H), 7.11 (s, 1 H), 3.93 (s, 3 H), 3.72 (s, 3 H), 1.49 (s, 9 H).
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C NMR (300 MHz, DMSO-d6)  = 174, 162.6, 152.5, 144.9, 144.4, 130.8, 126,

13

124.2, 123.5, 79.5, 37.3, 34.8, 28.4. HRMS (ESI) calculated for C16H21N5O5 [MH]+,
363.37, found, 363.15.
2.2.4 Synthesis of Boc-Py-Im-γ-Py-β-Pam via the solid-phase method
The sequence of 2 and all the following sequences in the next
chapter have been prepared using the CSBio synthesizer (model CS136XT), as showing
in (Figure 2.8). First, the CSBio reaction's vessel was heated at 35 ℃ for 10 min. Then,
Boc-Beta-Ala-Pam resin (1 g, 0.23 meq/g) was transferred to the reaction vessel. PyBOP
(benzotriazole-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate) (10 g, 19.25
mmol) in DMF (36 mL) was transferred to the R4 vessel. After 3 h, a solution of BocPyOBt (0.74 g, 2.08 mmol) in DMF (6 mL) was stirred for 5 min then transferred to the
amino acid reservoir (AA# 1). Each sequence takes approximately 5 h to complete. Every
building block, either monomer or dimer, must prepare at the last min to keep the
carboxylic group stable in the solution. After the first sequence was compeleted, a
solution of Boc-γCOOH (0.42 g, 2.08 mmol) in DMF (6 mL) was stirred for 5 min then
transferred to AA# 2. A dimer of Boc-Py-ImCOOH (0.56 g, 1.56 mmol), PyBOP (0.82 g,
1.56 mmol), and N, N-diisopropylethylamine DIEA (1mL, 5.7 mmol) in DMF (6 mL)
were stirred for 5 min then transferred to AA# 3 at the last min.
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Figure 2.8. Automated Peptide Synthesizer.

The addition of one building block includes deprotection, coupling, and capping
steps, with washing between each step, and this is repeated for each successive building
block (Figure 2.9).
Polyamide 2 was built with three synthesis protocols (CFN), as shown (Table
2.1).

Table 2.1. Automated Peptide Synthesizer Protocols.
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Figure 2.9. Solid Phase Synthesis Scheme of Polyamide 2. Starting from
commercially available Boc-β-pam resin: (i) wash with DCM and DMF; (ii) 60%
TFA/DCM/0.5M indole; (iii) 25% piperidine/DMF; (iv) building block; (v) 0.5M
PyBOP/DMF; (vi) DIEA; (vii) DMSO; (viii) capping with acetic anhydride.

2.2.5 Cleavage of PAM resin residue using Dp polyamine as a nucleophile
After the synthesis of 2 was completed, all resin was removed from the reaction
vessel and washed three times with DMF, DCM, and MeOH, then dried under vacuum
for 20 min. Compound 2 (1.54 g) was transferred into an empty polypropylene vial, and
Dp (3- dimethylamino-1-propylamine) (4 mL, 41 mmol) was added to the resin. The
resin was heated with Dp solution at 60 ℃ for 4 h using an Isotemp Fisher Scientific.
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After heating, the separation of polyamide solution from the resin support was
performed on a 20 µM polyethylene frit placed inside a disposable polypropylene syringe
by washing with MeOH (Figure 2.10). The polyamide solution was concentrated in
vacuum to afford 600 mg of 2 (0.82 mmol, 60% yield).

Figure 2.10. Separation of Polyamide Solution from the
Resin Support.

2.2.6 Purification of BocPy-Im-γ-Py-β-Dp
The polyamide solution was diluted with a 50:50% mixture of 600 µL DMSO and
600 µL H2O/ 0.2% HCOOH, then purified by reverse-phase HPLC using a Phenomenex
Luna 250 x 30 mm, 5 μM, 100 Å, C18 (version 2) column maintained at 25 ˚C. The
organic phases were 0.2% formic acid in water (A) and 100 % methanol (B). The applied
gradient was 10 % B for 2 min, followed by a ramp to 90 % B over 35 min at 20 mL/min.
All pooled fractions were concentrated in vacuum to remove the MeOH from the
solution.
2.2.7 Lyophilization of BocPy-Im-γ-Py-β-Dp
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A solution of 2 (1.28 g, 1.76 mmol) diluted with a 50:50 % mixture of ACN (2
mL), and 0.2 %/ H2O (2 mL). The samples were frozen before lyophilization using dry
ice and rotating until an even coating of frozen material results at an acute angle in the
container.
The vial with the frozen sample was covered with porous Kimtech/Kimwipe
paper and secured with a rubber band and transferred into a lyophilizer vessel and the
vessel was connected to a vacuum port. The frozen polyamide converted to a solid
powder after 24 h. The lyophilizer vacuum was set at 300 torr within 30 minutes, and the
temperature was set at -83 ℃.
2.2.8 Characterization of BocPy-Im-γ-Py-β-Dp
Analytical HPLC characterization was carried out using a Phenomenex Jupiter
Proteo (C12) column, 4.6 x 50 mm, 4 μ, 90 Å column maintained at 40˚C. The mobile
phases consisted of 0.1% trifluoroacetic acid in water (A) and 100 % acetonitrile (B). The
applied gradient consisted of 5% B for 0.75 min, followed by a ramp to 60% B over 6.5
min at 1 mL/min. The retention time was 2.273 min.
PA2 Boc-Py-Im-Ƴ-Py-β-Dp (HCOO-)2:
1

H NMR (600 MHz, DMSO-d6)  = 10.45 (s, 1 H), 9.88 (s, 1 H), 8.37 (s, 2 H),

7.49 (s, 1 H), 7.09 (s, 1 H), 6.90 (s, 2 H), 6.28 (s, 1 H), 6.62 (s, 2 H), 3.92 (s, 3 H), 3.86
(s, 3 H), 3.76 (s, 3 H), 3.35-3.32 (m, 2 H), 3.29-3.26 (m, 2 H), 3.06-3.03 (m, 2 H), 2.88
(br. s., 1 H), 2.30-2.29 (t, J = 3.35 Hz, 2 H), 2.27- 2.24 (t, J = 7.64 Hz, 2 H), 2.17 (s, 9 H),
2.08 (s, 1 H), 1.80- 1.76 (m, 2 H), 1.56-1.52 (m, 2 H).
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C NMR (151 MHz, DMSO-d6)  = 170.4, 168.9, 165.3, 161.1, 158.6, 158.1,

13

157.9, 135.9, 134, 123.4, 122.8, 121.9, 121.3, 120.2, 117.6, 114.1, 106.1, 103.3, 56.2,
44.4, 37.9, 36.6, 36.4, 35.8, 35.5, 35.4, 34.8, 33, 30.6, 26.5, 25.5.
HRMS (ESI) calculated for C34H51N11O7 [MH]+, 726.3975, found, 726.4053.
HPLC purity: 98%. (Figure 2.11).

Figure 2.11. HPLC Purity of Synthesized polyamide with  Monitored. PA2
98% purity, retention time 2.27 min.

2.3 Results and Discussion

40

Polyamide 2 was synthesized by the solid-phase method, as described early in this
chapter. For the Boc-Py-ImCOOH dimer, the starting material was NO2-Im-CO2Me,
which is commercially available. Most available procedures offered only milligram to
gram quantities of the dimer, meanwhile requiring difficult column chromatography in
the purification process.18-20
Therefore, inexpensive starting material 3 was utilized, allowing Boc-PyImCOOH 7 dimer to be prepared in high yield without using column chromatography.
Some factors must be considered through the experiment, such as the Pd catalyst cost,
high isolated yields, and safe handling.21 The reaction of 3 in the presence of 10% Pd/C
catalyst with ammonium formate has led to a low yield when refluxed for 4 h. Therefore,
to optimize our reaction, we used Pearlman's catalyst (palladium hydroxide on carbon) in
the presence of ammonium formate to obtain a high yield of 4 with less refluxing time
(Table 2.2).
Compound

Catalyst

Time of refluxing

Yield%

(h)
3

10% Pd/C

4

44

3

20% Pd/C

2

83

Table 2.2. Hydrogenation of NO2-ImCOOMe in the Presence of Ammonium
Formate. Using 10% Pd/C gave 44% while, 20% Pd/C offered 83% with less time
of refluxing.

The presence of two nitrogen atoms in the imidazole ring makes the NH2 group a
weak nucleophile. That can be attributed to the strong electron-withdrawing effect of the
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two nitrogen atoms inside the imidazole ring.22 Therefore, we prepared a dimer of 7 to
avoid any failure binding between the amine and carboxylic groups. The coupling
reaction between 4 and 5 was dominated by electrophilicity of the carboxyl component
and nucleophilicity of the amine component. However, the three nitrogen atoms on the
benzotriazole group (OBt) on 5 make this group highly electronegative. This might
activate the carbonyl group on pyrrole and make it more easily attacked by the
nucleophile. For solid-phase synthesis, polyamide 2 was built on an insoluble matrix by
linking each building block via an amide bond. Building this polyamide consisted of
adding one BocPy-OBt monomer (OBt = benzotriazole ester), one Boc-γ-COOH
monomer, and a dimer of BocPy-Im-COOH to Boc-β-PAM resin in sequential reactions.
The β-alanine-PAM resin has been used reliably in our lab since it is compatible with
Boc protection-deprotection methodology and affords convenient cleavage methods for
polyamides using Dp or Ta polyamine nucleophiles. Attaching C-terminal β-alanine to
the resin was necessary to facilitate solid-phase synthesis and increase both affinity and
specificity.22 On the other hand, the cleavage of polyamide 2 from the solid support resin
was successful and reliable. The polyamide might be irreversibly modified or ruined
unless suitable reagents and reaction conditions are precisely selected. Therefore, various
temperatures have been applied for cleavage to avoid polyamide decomposition. We
found that cleavage at 60 ℃ with Dp solution for four hours led to favorable results
(Table 2.4). We obtained a low yield (25%) when a temperature of 30 ℃ for 2 h was
applied. Cleaving at 35 ℃ for 6 h has led to better yield (29%), but still not convenient
yet. We decided to jump to a higher temperature for a long time when we did the
cleavage at 80 ℃ for 5 h. We have observed that the target polyamide was ruined
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completely under these conditions, and the yield went down to zero. We optimized the
yield when 60 ℃ for 4 h was applied to obtain the product 2 in 60% yield after the
lyophilizing process.
Polyamide

Applied temperature ℃

Time of heating h

Yield %

2

30

2

25

2

35

6

29

2

80

5

0

2

60

4

60

Table 2.4. Cleavage the Target Polyamide under Different Temperature and Time.
Cleaving at 60 ℃ for 4 h has offered good yield.

2.4 Conclusions
In summary, a convenient method for synthesis polyamide 2 on the solid support
resin has been successfully applied. We have synthesized a molecule that mimics the
truncated green portion of UMSL1011, which was active against VSV.9 We have used
the same building blocks as in UMSL1011 by linked them step by step with β-alanine
PAM resin via solid-phase methods. Polyamide 2 has been built on an insoluble support
resin using a CSBio peptide synthesizer.
The first building block in the chain (BocPyImCOOH) is commercially available
but is very expensive. Therefore, synthesizing this dimer in the lab reduced the cost. The
reaction of methyl 1-methyl-4-nitro-1H-imidazole-2-carboxylate 3 with Pearlman's
catalyst in the presence of ammonium formate gave an 83% yield of 4. However, using
10% Pd/C with H2 at atmospheric pressure led to a low yield of the same compound.
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From a practical point of view, decreasing the amount of expensive Pd catalyst
was one of our priorities in this project. In this research, we used a convenient procedure
to prepare an essential dimer Boc-Py-ImCOOH 7 with no need for column
chromatography. The two nitrogen atoms inside the imidazole ring make the NH2 weak
nucleophile.22
Therefore, synthesizing the dimer 7 has reinforced the binding between the amine
and carboxylic groups. Cleaving of PAM resin from sequence 2 was accomplished using
the strong diamine nucleophile (Dp) under mild conditions. We have optimized the yield
by applied several temperatures with different heating times. We found that cleavage at
60 ℃ for 4 h led to adequate yield.
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Chapter 3
Synthesis of Several Short-Long Chains of Positive and
Neutral N-Terminal Polyamides Against VSV via SolidPhase Methods

48

3.1 Introduction
Existing small molecules preferentially bind to specific DNA sites inside living
cells be considered useful in molecular biology and perhaps human medicine. Some of
these small molecules' prominent features include DNA minor groove binding and cellpermeability to gain access to the nucleus of living cells.1-2 N-methylpyrrole (Py) and Nmethylimidazole (Im) hairpin polyamides (PAs) are heteroaromatic compounds that can
bind to the minor groove of A/T-rich DNA and are inspired by the chemical structures of
the natural antibiotic’s distamycin A and netropsin.3-4
These small molecules, collectively known as polyamides, often possess an
antiparallel nature that allows for the side-by-side pairing of building blocks and
recognizing DNA base pairs (bp) within a double strand (dsDNA). Researchers have
extensively reported the pairing roles of polyamides moieties where Py/Py and Py/βalanine (β) pairs recognize A/T and T/A base pairs, while an Im/Py pair distinguishes
G/C from C/G.5-6 Moreover, it has been extensively reported that substituting the flexible
β linker can facilitate long DNA sequences targeting and reset the heterocycle-base pair
register.7-8 In numerous biomedical applications, synthetic hairpin PAs were attractive for
many researchers worldwide since they could recognize DNA sequences by binding to
patterns of hydrogen-bond donors and acceptors in the minor groove of DNA.8-11 Thus,
the application of polyamides can include biological imaging, regulation of gene
expression, and antimicrobial/antiviral agents.12-13 Various polyamides have proved a
potent activity against papillomaviruses and polyomaviruses by decreasing viral DNA
concentration from 50-90% in cell culture.14-15
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However, binding to RNA was a gamble because research has shown that these
polyamides do not bind well to double-stranded RNA.16-17 We hypothesized that the
diverse structures found in single-stranded RNA genomes would provide promising
targets for polyamides, and this proved correct with UMSL1011 and VSV. Vesicular
stomatitis virus VSV mainly affects rodents, cattle, swine, and horses but can also infect
humans and other species. Researchers believe VSV spreads between hoofed animals and
rodents via insect vectors.18
It features a single RNA strand of negative polarity entirely coated by the viral
nucleoprotein and replicates entirely within the cytoplasm. During infection, five
subgenomic mRNAs that encode its five distinct proteins are synthesized.19 Of specific
interest to this research, polyamides have proved a potential activity to interact with viral
genomic RNA encapsulated inside the nucleocapsid. VSV was chosen as a preliminary
model for testing PAs' binding before looking for anti-RSV effects because its virology is
similar to that of RSV. As we mentioned earlier, one polyamide molecule, UMSL1011,
was found to inhibit replication of VSV, allowing cells to remain alive after infection
with this lytic virus.20 Professor Luo and his team constructed a nucleocapsid-like particle
(NLP) with polyamide and demonstrated that UMSL1011 targeted the nucleocapsid,
increasing the melting temperature of the RNA-filled NLP. Furthermore, the
encapsidated RNA in the polyamide-treated NLP was protected from thermo-release and
RNase A digestion.
Luo and his team also found that UMSL1011 inhibited viral RNA synthesis in the
intracellular activity assay for the viral RNA-dependent RNA polymerase. Examination
of the crystal structure revealed that UMSL1011 binds the structured RNA in the
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nucleocapsid.20 Moreover, Nucleocapsid N is a particle containing a protein coat and
single-strand RNA genome. NSV also encodes an RNA‐dependent RNA polymerase
(vRdRp) in their genomes. For viral RNA synthesis to occur, the vRdRp must gain access
to the RNA genome protected in the nucleocapsid particle during RNA synthesis. The
vRdRp will be disabled to recognize the RNA as a template for viral RNA synthesis if the
RNA genome is emancipated from the nucleocapsid as a free RNA molecule or if the
genomic RNA is locked into a specific conformation within the NLP, preventing the
RNA from moving as required during the copying process.20-22
The Luo group decided to start working on VSV rather than RSV because RSV is
so toxic to cells that it is challenging to work with unless a highly active antiviral has
been discovered.20 However, there are many similarities in the lifecycles of VSV and
RSV. Therefore, the skills and techniques learned will theoretically be transferable to
work with RSV in later research. This research aims to synthesize and characterize
several short-long sequences of polyamides by introducing positive and neutral Nterminus groups with changing one or two building blocks in the designed compounds
via solid-phase methods.
3.1.1 Solid-Phase Peptide Synthesizer
Peptide synthesis is a useful technique that enables the preparation of materials
ranging from small peptides to large proteins.7,10 In 1966, Bruce Merrifield developed the
CS336 peptide synthesizer using the solid-phase peptide synthesis method (SPPS).23 His
pioneering work has dramatically changed the peptide synthesis strategy and simplified
the tedious and demanding steps of purification associated with the solution-phase
synthesis.23 For a long time, our lab has successfully synthesized several short and long
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chains of polyamides as antiviral agents using the CSBio machine.24-25 The polyamide
can be generated on a solid support resin such as Boc-beta-alanine-PAM resin. Boc-βPAM resin has been used reliably in our lab since it is compatible with Boc-protection
and deprotection methodology. Furthermore, this resin can afford simple cleavage
methods for different polyamides using polyamine Dp or Ta as nucleophiles (Figure
3.1).26-27

Figure 3.1. Structure of Boc-beta-alanine-PAM Resin.

The CSBio peptide synthesizer contains a glass reaction vessel with a plastic frit
to keep the resin in and allow the addition and removal of solvents and dissolved amino
acids (Figure 3.2). The resin's mixing is accomplished by a gentle air-driven inversion
required to ensure complete resin to solvent (or amino acid) contact.

Figure 3.2. Peptide Synthesizer Flow Chart. MVA is metering vessel
A, MVB is metering vessel B, TVA is transferred vessel A, TVB is
transferred vessel B, S symbol is a sensor, RV is the reaction vessel.
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The instrument contains nine standard reagent bottles numbering from R1 to R9.
These reagent bottles are filled with appropriate solvents, acids, and bases required for
polyamide synthesis (Table 3.1).
Reagent bottles

Chemical reagents

R1

DMF

Functions
it is a mildly polar solvent that is infinitely miscible
with the other chemical reagents used during
synthesis, making them excellent for doing washes.

R2/R6

DCM

Same function of DMF. Washing the resin
frequently with DCM/DMF will facilitate
penetrating sample molecules with resin and
optimizing the binding activity.

R3

DMSO

Similar functionality to DMF/DCM has a slightly
different molecular shape and polarity, potentially
making different couplings

R4

0.5 M
PyBOP/DMF

R5

DIPEA

Aid in coupling reactions between carboxylic and
amines groups.
A mild base functions as an activator for the
PyBOP and removes the polyamide bonding
process during the coupling stage.

R7

2.6% indole/60%

TFA is Powerful acid that rips the Boc group off.

TFA/40% DCM

Indol is a "scavenger" that soaks up impurities as
they are cleaved off the resin along with the final
polyamide.

R8

Ac2O

This compound is highly reactive and caped any
amine that fail to react in the previous coupling
step.

R9

25%

Piperidine is a very strong base that removes the

Piperidine/DMF

Boc group from the end of polyamide and frees up
the next bond.

Table 3.1. Type of Reagents in Polyamide Synthesis Using CSBio Synthesizer.
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The automated peptide synthesizer's main components are reagent bottles,
reaction vessels, metering vessels, the metering vessel of amino acids, transfer vessels,
and sensors. The synthesizer consists of nine solvent reservoirs containing the solvents
used during the polyamide synthesis. The instrument also contains 22 amino acid
reservoirs to hold the pyrrole/imidazole samples used during the synthesis.
The solvent delivery, mixing, and solvent removal are three essential steps
required for polyamide synthesis. MVA can measure solvents from R1-R5 while MVB
from R6-R9. Moreover, the instrument contains 16 sensors, and each sensor has a
specific function, but the essential sensor is sensor two, which is the standard wash
volume, typically 8 mL.
In the previous chapter, we synthesized new molecules (Figure 2.9) based on the
truncated green portion of UMSL1011 (Figure 2.2). The goal to make several positive
and neutral chains of short polyamides has encouraged us to synthesize more than one
sequence of the same molecule (compound 2 Figure 2.9). The newly designed molecules
possessed the same building blocks of the truncated portion of UMSL1011, except for
replacing the Boc group on pyrrole moiety with positive and neutral N- terminal groups,
such as tetramethylguanidine (TMG), guanidinium (Guan), and N-formyl amine (NF)
groups. Furthermore, replacing the Boc-pyrrole moiety in the newly designed molecule
with dImCO2H was necessary to optimize the activity against VSV. Our ambition was
not to synthesize only a short sequence of polyamides; the willingness to study the
interaction between polyamide molecules and structured RNA into the nucleocapsid
motivated us to design several long chains of polyamides. Here, we synthesized and
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characterized several long-short sequences of polyamide molecules via solid-phase
synthesis methods according to the truncated active portion of UMSL1011 (Table 3.2).
N-

1

2

3

4

5

6

7

8

9

10

11

12

13

terminus

Cterminus

TMG-Py

Im γ

Py

β

Dp

Guan-Py

Im γ

Py

β

Dp

NF-Py

Im γ

Py

β

Dp

dIm

Im γ

Py

β

Dp

dIm

Py

Py

Im Py

TMG-Im

β

Im γ

Py

TMG-Py

β

Im Py

Im γ

dIm

Py

β

Im γ

TMG-Im

Py

Py

Guan-Im

Py

dIm
dIm

γ

β

Dp

β

Py β

Dp

Py Py

β

Dp

Py

Py β

Py β

Dp

Im γ

Py

Py Py

Py β

DP

Py

Im γ

Py

Py Py

Py β

Dp

Py

β

Py

Py

Im Py Py

β

Im β

Dp

Py

β

Py

Py

Py

Py Py Py Py β

Dp

Py Im γ

Table 3.2. New Designed Polyamides via CSBio Machine with Their Building Blocks.

3.2 Methods
3.2.1 Materials
Boc-beta-alanine-Pam resin was ordered from Peptides International (Louisville,
KY), 3-(Dimethylamino)-1-propylamine, piperidine, indole, ammonium formate,
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palladium hydroxide on carbon, HCl, NaOH, and N-methylimidazole, were purchased
from Sigma Aldrich (St. Louis, MO), methyl 1-methyl-4-nitro-1H-imidazole-2carboxylate I was ordered from AC Pharmachem, Inc (Worcester, MA), 4-tertbutoxycarbonylamino-1-methyl-1H-pyrrole-2-carboxylic acid benzotriazole-1yl ester,
HATU, PyBOP, 4-tert-butoxycarbonylaminobutyric acid, Boc-Beta-alanine carboxylic
acid, MeOH, dioxane, DMF, DCM, and trifluoroacetic acid was acquired from Oakwood
Chemical (N. Estill, SC), N, N-diisopropylethylamine, formic acid, and acetic anhydride
were obtained from Fisher Scientific (St. Louis, MO).
3.2.2 Synthesis of TMG-Py-Im-γ-Py-β-Dp
In the previous chapter, we have discussed synthesizing a dimer of Boc-PyImCO2H via solution-phase methods (see Figure 2.7). We used the same dimer in
synthesizing the current sequence 11 and the following sequences in this chapter. The
CSBio synthesizer (model CS136XT) was used to synthesize the above sequence and the
next sequences in this research. First, The CSBio was heated at 35 ℃ for 10 min. BocBeta-Ala-Pam resin 2 (1.03 g, 0.24 meq/g) was transferred to the reaction vessel. PyBOP
(benzotriazole-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate) (12 g, 23.1
mmol) dissolved in DMF (38 mL) and transferred to the R4 vessel. After 3 h, a solution
of Boc-PyOBt 3 (0.70 g, 1.98 mmol) in DMF (6 mL) was stirred for 5 min then
transferred to the amino acid reservoir (AA# 1). Each sequence takes approximately 5 h
to complete. Every building block, either monomer or dimer, must prepare at the last min
to keep the carboxylic group stable in the solution. After the first sequence was
completed, a solution of Boc-γCOOH 5 (0.45 g, 2.23 mmol) in DMF (6 mL) was stirred
for 5 min then transferred to AA# 2. A dimer of Boc-Py-Im-COOH 7 (0.50 g, 1.39
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mmol), PyBOP (0.79 g, 1.50 mmol), and N, N-diisopropylethylamine DIEA (1mL, 5.7
mmol) in DMF (6 mL) were stirred for 5 min then transferred to AA# 3 at the last min.
After 3 h, a solution of HATU (1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5b] pyridinium 3-oxide hexafluorophosphate) 9 (0.85 g, 2.24 mmol) in DMF (6.5 mL) was
stirred for 5 min then transferred to the amino acid reservoir (A# 4) to introduce a TMG
group on the sequence (Figure 3.3).

Figure 3.3. Scheme of TMG-Py-Im-γ-Py-β-PAM resin. Starting from commercially
available Boc-β-pam resin: (i) wash with DCM and DMF; (ii) 60% TFA/DCM/0.5M
indole; (iii) 25% piperidine/DMF; (iv) building block; (v) 0.5M PyBOP/DMF; (vi) DIEA;
(vii) DMSO; (viii) capping with acetic anhydride.
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The addition of each building block was submitted to deprotection, coupling, and
capping steps, with washing between each step, which is repeated for each successive
building block. Polyamide 10 has been built with seven consecutive programs, as shown
(Table 3.3).
Building blocks

Applied programs

1 – Boc-PyOBt

Add- DIEA-180 min-DIEA-Flows-CFN

2 - Capping

Cap- 17 min- continue-CFN

3 – Boc-γCOOH

Add-DIEA-PyBOP-180 min- DMSO-DIEA-Flows-CFN

4 - Capping

Cap- 17 min- continue-CFN

5 – Boc-Py-ImCOOH

PreAct-180 min- DMSO-DIEA-Flows-CFN

6 - Capping

Cap- 17 min- continue-CFN

4 – HATU Solution

Add-TMG-DIEA-180 min- DMSO-DIEA-Flows-CFN

Table 3.3. Used Applied Programs in the Synthesis of Polyamide
10.

3.2.3 cleavage of PAM resin residue using Dp as a Nucleophile
After the synthesis of 10 was completed, all resin was removed from the reaction
vessel and washed three times with DMF, DCM, and MeOH, then dried under vacuum
for 15 min. Compound 10 (1.55 g) was transferred into an empty polypropylene vial, then
Dp (3- dimethylamino-1-propylamine) (4 mL, 41 mmol) was added to the resin. The
resin was heated with Dp solution at 38 ℃ for 23 h using an Isotemp Fisher Scientific.
After heating, the separation of polyamide solution from the resin support was
performed on a 20 µM polyethylene frit placed inside a disposable polypropylene syringe
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by washing with MeOH. Polyamide solution was concentrated in vacuum to afford 400
mg (0.55 mmol, 39% yield) (Figure 3.4).

Figure 3.4. Cleaved Polyamide 11 Via Dp.

3.2.4 Purification of TMG-Py-Im-γ-Py-β-Dp
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The polyamide solution was diluted with a 50:50% mixture of 600 µL DMSO and
600 µLH2O/ 0.2% HCOOH, then purified by reversed-phase HPLC using a Phenomenex
Luna 250 x 30 mm, 5 μM, 100 Å, C18 (version 2) column maintained at 25 ˚C. The
organic phases were 0.2% formic acid in water (A) and 100 % methanol (B). The applied
gradient was 2 % B for 10 min, followed by a ramp to 80 % B over 40 min at 20 mL/min.
All pooled fractions were concentrated in vacuum to remove the MeOH from the
solution.
3.2.5 Lyophilization of TMG-Py-Im-γ-Py-β-Dp
Compound 11 was diluted with a 50:50% mixture of ACN (3 mL), and 0.2 %/
H2O (3 mL). The samples were frozen before lyophilization by rotating them in dry ice
until an even coating of frozen material resulted at an acute angle in the container.
The frozen samples in the vial were covered with porous Kimtech/Kimwipe
paper secured with a rubber band. All samples were transferred into a lyophilizer vessel
and connected to a vacuum port. The polyamide converted to an orange-yellow powder
after 48 h. The lyophilizer vacuum was set at 300 torr within 30 minutes, and the
temperature was set at -83 ℃.
3.2.6 Characterization of TMG-Py-Im-γ-Py-β-Dp
Analytical HPLC characterization was carried out using a Phenomenex Jupiter
Proteo (C12), 4.6 x 50 mm, 4 μ, 90 Å column maintained at 40 ˚C. Mobile phases
consisted of 0.1% trifluoroacetic acid in water (A) and 100 % acetonitrile (B). The
applied gradient consisted of 5% B for 0.75 min, followed by a ramp to 60% B over 6.5
min at 0.75 mL/min. The retention time was 3.647 min.
PA11 TMG-Py-Im-γ-Py-β-Dp (HCOO-)3:
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1

H NMR (600 MHz, DMSO-d6)  = 10.46 (s, 1 H), 9.89 (s, 1 H), 8.37 (s, 1 H),

8.01 (s, 1 H), 7.92 (s, 1 H), 7.49 (s, 1 H), 7.09 (s, 2 H), 6.90 (s, 1 H), 6.81 (s, 2 H), 6.62
(s, 1 H), 3.92 (s, 3 H), 3.86 (s, 3 H), 3.76 (m, 3 H), 3.35-3.32 (m, 2 H), 3.92-3.26 (m, 2
H), 3.06-3.03 (m, 2 H), 2.31-2.29 (t, J = 7.003 Hz, 2 H), 2.27-2.24 (t, J = 7.51 Hz, 2 H),
2.17 (s, 12 H), 2.14 (s, 6 H), 1.80-1.76 (m, 2 H), 1.69-1.65 (m, 2 H), 1.56-1.52 (m, 2 H).
C NMR (151 MHz, DMSO-d6)  = 169.9, 168.5, 164.8, 160.6, 158.2, 157.7,

13

157.5, 135.5, 133.6, 122.9, 122.3, 121.4, 120.9, 119.7, 117.1, 113.6, 105.6, 102.9, 55.7,
44.4, 37.5, 36.2, 36.3, 35.4, 35.1, 34.9, 34.3, 32.6, 26.1, 25.1.
HRMS (ESI) calculated for C34H53N13O5 [MH]+, 723.4295, found, 723.4405.
HPLC purity: 98%. (Figure 3.5).

Figure 3.5. HPLC Purity of Polyamide11 with  Monitored.
PA11, 98% purity, retention time 3.647 min.
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3.2.7 Synthesis of Guan-Py-Im-γ-Py-β-Dp
Synthesis of polyamide 22 was started by heating the CSBio reaction's vessel at
35 ℃ for 10 min. After 20 min, Boc-Beta-Ala-Pam resin 12 (1.1 g, 0.25 meq/g) was
transferred to the reaction vessel. PyBOP (benzotriazole-1-yloxytripyrrolidinophosphonium hexafluorophosphate) (14 g, 26.95 mmol) was dissolved
in DMF (44 mL) and transferred to the R4 vessel. After 3 h, a solution of Boc-PyOBt 13
(0.76 g, 2.14 mmol) in DMF (6 mL) was stirred for 4 min then transferred to the amino
acid reservoir (AA# 3). After the first sequence was finished, a solution of Boc-γCOOH
15 (0.48 g, 2.37 mmol) in DMF (6 mL) was stirred for 6 min and transferred to AA# 4.
After sequence 2 was completed, a dimer of Boc-Py-ImCOOH 17 (0.55 g, 1.53 mmol),
PyBOP (0.82 g, 1.56 mmol), and N, N-diisopropylethylamine DIEA (1 mL, 5.7 mmol) in
DMF (6.3 mL) were stirred for 7 min then transferred to (AA# 5) at the last min.
To check sequence completion, 0.1 mg of the resin was cleaved with 100 µL Dp
solution for 1 h at 60 ℃, then the heated mixture was filtered with MeOH, and 5 µL were
injected into an LC-MS instrument. The exact mass was determined to be 726.4976
[MH]+. All the resin was collected from the R.V. and washed three times with DMF,
DCM, and MeOH, then dried under vacuum for 12 min and kept in the freezer.
On the next day, the entire resin was transferred to the R.V to complete the
reaction. After 3 h, a solution of Bis-Boc-Pyrazolocarboxamidine 19 (0.85 g, 2.74 mmol),
DIEA (1mL, 5.7 mmol) in DMF (6 mL) were stirred for 5 min and transferred to the R.V
through a 10 min pause step. The sequence was finished after 26 h. Deprotection of the
(Boc)2 group on the guanidinium group using a TFA solution was the last step to
introduce the Guan group in the sequence (Figure 3.6).
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Figure 3.6. Scheme of Guan-Py-Im-γ-Py-β-PAM resin. Starting from commercially
available Boc-β-pam resin: (i) wash with DCM and DMF; (ii) 60% TFA/DCM/0.5M
indole; (iii) 25% piperidine/DMF; (iv) building block; (v) 0.5M PyBOP/DMF; (vi) DIEA;
(vii) DMSO; (viii) capping with acetic anhydride.
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Polyamide 21 was built with eight consecutive programs (Table 3.4).
Building blocks

Applied programs

1 – Boc-PyOBt

Add- DIEA- 180 min- DIEA- Flows-CFN

2 - Capping

Cap- 17 min- continue- CFN

3 – Boc-γCOOH
4 – Capping

Add- DIEA- PyBOP- 180 min- DMSO- DIEAFlows- CFN
Cap- 17 min- continue- CFN

5 – Boc-Py-ImCOOH

PreAct- 180 min- DMSO- DIEA- Flows- CFN

6 – Capping

Cap- 17 min- continue- CFN

7 – Guan Solution

1 gram- pause- 24 h- DMF- Flows- CFN

8 - Deprotection

DMF- DCM- TFA- DCM- Flows- CFN

Table 3.4. Used Applied Program in Synthesis of Polyamide 21.

3.2.8 Cleavage of Polyamide 21 Using Dp as a Nucleophile
After the synthesis of polyamide 21 was completed, the R.V glass was opened
and gently collected all the resin inside it using a stirring rod. The next step was placing
the resin on a filter paper inside a Buchner funnel and washed it three times with DMF,
DCM, and MeOH, and dried it under vacuum for 11 min. Compound 21 (1.58 g) was
transferred into an empty polypropylene vial, then Dp (3- dimethylamino-1-propylamine)
(6 mL, 61 mmol) was added to the resin. We were heating the resin with Dp solution at
45 ℃ for 11 h using an Isotemp Fisher Scientific.
After heating, the separation of polyamide solution from the resin support was
performed on a 20 µM polyethylene frit placed inside a disposable polypropylene syringe
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by washing with MeOH. Polyamide solution was concentrated in vacuum to afford 420
mg (0.63 mmol, 38% yield) (Figure 3.7).

Figure 3.7. Cleaved Polyamide 21 Via Dp.

3.2.9 Purification of Guan-Py-Im-γ-Py-β-Dp
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The polyamide solution was diluted with a 50:50% mixture of 800 µL DMSO and
800 µL H2O/ 0.2% HCOOH, then purified by reversed-phase HPLC using a Phenomenex
Luna 250 x 30 mm, 5 μM, 100 Å, C18 (version 2) column maintained at 25 ˚C. The
organic phases were 0.2% formic acid in water (A) and 100 % methanol (B). The applied
gradient was 10 % B for 8 min, followed by a ramp to 70 % B over 50 min at 20 mL/min.
All pooled fractions were concentrated in vacuum to remove the MeOH from the
solution.
3.2.10 Lyophilization of Guan-Py-Im-γ-Py-β-Dp
Compound 22 was diluted with a 50:50 % mixture of ACN (4 mL), and 0.2 %/
H2O (4 mL). The samples were frozen before lyophilization using dry ice and rotating
until an even coating of frozen material results at an acute angle in the container.
The frozen samples were covered vial with porous Kimtech/Kimwipe paper and
secured with a rubber band. All samples were transferred into a lyophilizer vessel and
connected to a vacuum port. The frozen polyamide converted to a fluffy yellow powder
after 42 h. The lyophilizer vacuum was set at 300 torr within 30 minutes, and the
temperature was set at -83 ℃.
3.2.11 Characterization of Guan-Py-Im-γ-Py-β-Dp
Analytical HPLC characterization was carried out using a Phenomenex Jupiter
Proteo (C12), 4.6 x 50 mm, 4 μ, 90 Å column maintained at 40˚C. Mobile phases
consisted of 0.1% trifluoroacetic acid in water (A) and 100 % acetonitrile (B). The
applied gradient consisted of 5% B for 0.75 min, followed by a ramp to 60% B over 6.5
min at 0.75 mL/min. The retention time was 3.813 min.
PA22 Guan-Py-Im-γ-Py-β-Dp (HCOO-)3:
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1

H NMR (600 MHz, DMSO-d6)  = 10.35 (s, 1 H), 9.79 (s, 1 H), 9.50 (br. S., 1

H), 9.43 (s, 1 H), 7.50 (s, 1 H), 7.36 (br. S., 1 H), 7.08 (s, 2 H), 7.03 (s, 1 H), 6.65 (s, 5
H), 3.92 (s, 3 H), 3.87 (s, 3 H), 3.76 (s, 3 H), 3.37-3.34 (m, 2 H), 3.29-3.25 (m, 2 H),
3.11-3.08 (m, 2 H), 3.01-2.98 (m, 2 H), 2.74 (s, 1 H), 2.73 (s, 6 H), 2.34-2.32 (t, J = 7.26
Hz, 2 H), 2.26-2.24 (t, J = 7.33 Hz, 2 H), 1.80-1.71 (m, 4 H).
C NMR (151 MHz, DMSO-d6)  = 170.9, 169, 161.2, 158.6, 158.2, 156.8,

13

135.8, 134.1, 124.7, 123.7, 122.7, 121.9, 117.6, 116.5, 114.1, 110.4, 103.4, 54.6, 42.2,
38.1, 36.6, 35.9, 35.5, 35.4, 34.8, 33.1, 25.5, 24.4.
HRMS (ESI) calculated for C30H45N13O5 [MH]+, 667.3668, found, 667.3659.
HPLC purity: 98%. (Figure 3.8).

Figure 3.8. HPLC Purity of Polyamide22 with  Monitored. PA22,
98% purity, retention time 3.813 min.
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3.2.12 Synthesis of NF-Py-Im-γ-Py-β-Dp
Synthesis of polyamide 35 was started by heating the CSBio reaction's vessel at
35 ℃ for 10 min. After 20 min, Boc-Beta-Ala-Pam resin 27 (1.13 g, 0.26 meq/g) was
transferred to the reaction vessel. PyBOP (benzotriazole-1-yloxytripyrrolidinophosphonium hexafluorophosphate) (15 g, 28.87 mmol) was dissolved
in DMF (47 mL) and transferred to the R4 vessel. After 3 h, a solution of Boc-PyOBt 28
(0.72 g, 2.02 mmol) in DMF (6 mL) was stirred for 5 min then transferred to the amino
acid reservoir (AA# 4). After the first sequence was finished, a solution of Boc-γCOOH
30 (0.49 g, 2.41 mmol) in DMF (6 mL) was stirred for 6 min then transferred to AA# 5.
After sequence 2 was completed, a dimer of Boc-Py-ImCOOH 32 (0.58 g, 1.61 mmol),
PyBOP (0.80 g, 1.52 mmol), and N, N-diisopropylethylamine DIEA (1mL, 5.7 mmol) in
DMF (6.5 mL) were stirred for 6 min then transferred to (AA# 6) at the last min.
To check sequence completion, 0.1 mg of the resin was cleaved with 100 µL Dp
solution for 2 h at 55 ℃, then the heated mixture was filtered with MeOH, and 5 µL were
injected into an LC-MS instrument. The exact mass was determined to be 726.4976
[MH]+.
All the resin was collected from the R.V and washed three times with DMF,
DCM, and MeOH, and dried it under a vacuum for 12 min and kept it in the freezer. On
the next day, a solution of acetic, formic anhydride (N-formyl amide group) 25 was
prepared by adding formic acid (10 mL, 265 mmol) to acetic anhydride (20 mL, 212
mmol) with stirring at -5 ℃ for 30 min (Figure 3.9).28
The solution was left stirring gently at R.T for 15 min, then refluxed at 50 ℃ for 1
h. The next day, the entire resin was transferred from the freezer to the R.V to complete
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the sequence. After 3 h, (12 mL, 5 mmol) of acetic, formic anhydride solution was
transferred to the R.V through a 10 min pause step. The sequence was finished after 5 h
(Figure 3.10).

Figure 3.9. Synthesis of Acetic, formic anhydride.

Figure 3.10. Caption on next page
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Figure 3.10. Scheme of NF-Py-Im-γ-Py-β-PAM resin. Starting from commercially
available Boc-β-pam resin: (i) wash with DCM and DMF; (ii) 60% TFA/DCM/0.5M
indole; (iii) 25% piperidine/DMF; (iv) building block; (v) 0.5M PyBOP/DMF; (vi) DIEA;
(vii) DMSO; (viii) capping with acetic anhydride.

Polyamide 34 was built with seven consecutive programs (Table 3.5).
Building blocks

Applied programs

1 – Boc-PyOBt

Add- DIEA- 180 min- DIEA- Flows-CFN

2 - Capping

Cap- 17 min- continue- CFN

3 – Boc-γCOOH
4 – Capping

Add- DIEA- PyBOP- 180 min- DMSO- DIEAFlows- CFN
Cap- 17 min- continue- CFN

5 – Boc-Py-ImCOOH

PreAct- 180 min- DMSO- DIEA- Flows- CFN

6 – Capping

Cap- 17 min- continue- CFN

7 – Acetic, formic anhydride
Solution

1 gram- pause- 24 hrs- DMF- Flows- CFN

Table 3.5. Used Applied Program in Synthesis of Polyamide 34.

3.2.13 Cleavage of Polyamide 34 Using Dp as a Nucleophile
After the synthesis of 34 was completed, the R.V was opened and gently collected
all the resin inside it using a stirring rod. The next step was placing the resin on a filter
paper inside a Buchner funnel and washed it three times with DMF, DCM, and MeOH,
and dried it under a vacuum for 10 min. Compound 34 (1.68 g) was transferred into an
empty polypropylene vial, then Dp (3- dimethylamino-1-propylamine) (6 mL, 61 mmol)
was added to the resin. The resin was heated with Dp solution at 43 ℃ for 13 h using an
Isotemp Fisher Scientific.
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After heating, the separation of polyamide solution from the resin support was
performed on a 20 µM polyethylene frit placed inside a disposable polypropylene syringe
by washing with MeOH. The Polyamide solution was concentrated in vacuum to afford
490 mg (0.75 mmol, 43% yield) (Figure 3.11).

Figure 3.11. Cleaved Polyamide 34 Via Dp.
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3.2.14 Purification of NF-Py-Im-γ-Py-β-Dp
The polyamide solution was diluted with a 50:50% mixture of 800 µL DMSO and
800 µL H2O/ 0.2% HCOOH, then purified by reversed-phase HPLC using a Phenomenex
Luna 250 x 30 mm, 5 μM, 100 Å, C18 (version 2) column maintained at 25 ˚C. The
organic phases were 0.2% formic acid in water (A) and 100 % methanol (B). The applied
gradient was 4 % B for 12 min, followed by a ramp to 60 % B over 45 min at 20 mL/min.
All pooled fractions were concentrated in vacuum to remove the MeOH from the
solution.
3.2.15 Lyophilization of NF-Py-Im-γ-Py-β-Dp
Compound 35 was diluted with a 50:50 % mixture of ACN (4 mL), and 0.2 %/
H2O (4 mL). The samples were frozen before lyophilization using dry ice and rotating
until an even coating of frozen material results at an acute angle in the container.
The frozen sample was covered with porous Kimtech/Kimwipe paper and secured
with a rubber band. All samples were transferred into a lyophilizer vessel and connected
to a vacuum port. The frozen polyamide converted to a yellow powder after 49 h. The
lyophilizer vacuum was set at 300 torr within 30 minutes, and the temperature was set at 83 ℃.
3.2.16 Characterization of NF-Py-Im-γ-Py-β-Dp
Analytical HPLC characterization was carried out using a Phenomenex Jupiter
Proteo (C12), 4.6 x 50 mm, 4 μ, 90 Å column maintained at 40˚C. Mobile phases
consisted of 0.1% trifluoroacetic acid in water (A) and 100 % acetonitrile (B). The
applied gradient consisted of 5% B for 0.75 min, followed by a ramp to 60% B over 6.5
min at 0.75 mL/min. The retention time was 3.51 min.
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PA35 NF-Py-Im-γ-Py-β-Dp (HCOO-)2:
1

H NMR (600 MHz, DMSO-d6)  = 10.29 (s, 1 H), 10.08 (s, 1 H), 9.80 (s, 1 H),

8.28 (s, 1 H), 8.11 (s, 1 H), 7.99 (s, 1 H), 7.92 (s, 1 H), 7.47 (s, 1 H), 7.27 (s, 2 H), 7.09
(s, 1 H), 6.98 (s, 1 H), 6.62 (s, 2 H), 3.92 (s, 3 H), 3.83 (s, 3 H), 3.76 (s, 3 H), 3.36-3.33
(m, 4 H), 3.29-3.25 (m, 2 H), 3.07-3.04 (m, 2 H), 2.44-2.42 (t, J = 12.34 Hz, 2 H), 2.322.29 (t, J = 13.71 Hz, 2 H), 2.27 (s, 6 H), 1.81-1.77 (m, 2 H), 1.60-1.56 (m, 2 H).
C NMR (151 MHz, DMSO-d6)  = 170.1, 169, 161.2, 158.7, 158.5, 157.9, 136,

13

134.1, 122.7, 122.1, 121.9, 120.8, 119.5, 119.1, 117.7, 117.4, 114.4, 55.8, 44.1, 43.8,
38.1, 36.1, 36.2, 35.9, 35.8, 35.5, 34.7, 26.1, 25.5.
HRMS (ESI) calculated for C30H43N11O6 [MH]+, 653.3399, found, 653.3517.
HPLC purity: 96%. (Figure 3.12).

Figure 3.12. HPLC Purity of Polyamide35 with  Monitored.
PA35, 96% purity, retention time 3.51 min.
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3.2.17 Synthesis of dIm-Im-γ-Py-β-Dp
Synthesis of NH2-Im-CO2Me
A solution of NO2-Im-CO2Me 36 (25 g, 135 mmol) and ammonium formate (35 g,
555 mmol) in ethyl acetate (200 mL) was stirred at 23 ℃ for 30 min. Pearlman's catalyst
(palladium hydroxide on carbon) 10 g was added to the mixture, and then refluxed for 3 h.
All catalysts have removed via filtration through Celite; then, the filtrate was
concentrated in vacuum to take the solvent off, then finally 20 g (129 mmol, 80% yield) of
a yellow-orange crude solid was obtained (Figure 3.13).29

Figure 3.13. Synthesis of NO2-Im-CO2Me.

Synthesis of Im-COCCl3
A solution of trichloroacetyl chloride (114 g, 623 mmol) in acetonitrile (625 mL)
was stirred at -10 ℃ for 15 min. 1-methyl- 1 H-imidazole 39 (51.5 g, 627 mmol) was
added slowly for 2 h while maintaining the solution's temperature at -10 ℃. The reaction
was left stirring at R.T for 1 h, then cooled again at -10 ℃. In the next step, N-methyl
morpholine (59.8 g, 591.20 mmol) was added slowly to the mixture with keeping the
temperature at -10 ℃ for 1 h. The solution was left stirring at R.T for 20 h. On the next
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day, the solution was concentrated in vacuum to take the solvent off. The solution was
washed three times with chloroform (100 mL), water (100 mL), and brine solution, then
dried it using MgSO4 anhydrous (10 g, 83 mmol). Filtered the solution using glass wool,
then concentrated it to take all chloroform off by vacuum. To the reaction mixture of
diethyl ether (75 mL) was added, and the solvent was removed under reduced pressure,
then completion of the reaction was monitored by TLC.
The crude mixture was purified by dissolving it in boiling hexane (100 mL), then
filtered the boiling mixture quickly and removed the hexane by vacuum, then finally 46 g
(192 mmol, 89% yield) of a light yellow-crystal solid was obtained (Figure 3.14).30

Figure 3.14. Synthesis of Im-COCCl3.

Synthesis of dIm-Im-OMe
A solution of NH2-Im-CO2Me 37 (22.8 g, 100 mmol) and Im-COCCl3 39 (15.5 g,
100 mmol) in ethyl acetate (400 ml) was stirred at R.T for 72 h. TLC checked the
reaction's completion; then, the mixture was concentrated in vacuum to remove the
solvent, then finally 20.6 g (74 mmol, 90% yield) of an orange crude solid was obtained
(Figure 3.15).29
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Figure 3.15. Synthesis of dIm-Im-COMe

Synthesis of dIm-Im-COOH
A solution of dIm-ImCO2Me 40 (20.6 g, 78.2 mmol) in MeOH (391 mL) was
stirred at R.T for 5 min, then NaOH (1 N, 391 mL, 391 mmol) was added to the mixture,
and the reaction left stirring for 4 hours. In the next step, decolorizing charcoal (10 g) was
added to the mixture and stirred for 1 h.
The mixture was filtered through a celite pad, and the PH adjusted to about 4.0 by
adding slowly 2 N HCl, then precipitate was formed after adding 391 mL H2O to the
solution. The solid was filtered and dried, then concentrated it in vacuum, and allowed to
stand at R.T to obtain 13.42 g (51 mmol, 68% yield) of a light-yellow powder (Figure
3.16).29

Figure 3.16. Synthesis of dIm-Im-COOH
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Compound41 dIm-Im-CO2H:
1

H NMR (600 MHz, DMSO-d6)  = 10.01 (s, 1 H), 7.62 (s, 1 H), 7.42 (s, 1 H),

7.05 (s, 1 H), 3.98 (s, 3 H), 3.93 (s, 3 H).
C NMR (151 MHz, DMSO-d6)  = 159.7, 156.1, 137.8, 135.6, 127.6, 126.9,

13

114.9, 35.6, 35.1.
HRMS (ESI) calculated for C10H11N5O3 [MH]+, 249.0862, found, 249.0941.
HPLC purity: 88%. (Figure 3.17).

Figure 3.17. HPLC Purity of dIm-Im-CO2H with  Monitored.
Compound 41, 88% purity, retention time 5.66 min.
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Synthesis of dIm-Im-γ-Py-β-Dp
Synthesis of polyamide 48 was started by heating the CSBio reaction's vessel at
35 ℃ for 10 min. After 20 min, transferred (1.133 g, 0.26 meq/g) of Boc-Beta-Ala-Pam
resin 42 to the reaction vessel. PyBOP (benzotriazole-1-yl-oxytripyrrolidinophosphonium
hexafluorophosphate) (9.5 g, 18.28 mmol) was dissolved in DMF (30 mL) and
transferred to the R4 vessel. After 3 h, a solution of Boc-PyOBt 43 (0.75 g, 2.1 mmol) in
DMF (6 mL) was stirred for 5 min then transferred to the amino acid reservoir (AA# 5).
After the first sequence was completed, a solution of Boc-γCOOH 45 (0.55 g, 2.7
mmol) in DMF (6 mL) was stirred for 6 min then transferred to AA# 6. After sequence 2
was completed, a dimer of dIm-ImCOOH 41 (0.56 g, 2.24 mmol), PyBOP (0.81 g, 1.53
mmol), and N, N-diisopropylethylamine DIEA (1 mL, 5.7 mmol) in DMF (6.5 mL) were
stirred for 8 min then transferred to (AA# 7) at the last min.
The sequence was completed after 5 h (Figure 3.18). To check sequence
completion, 0.1 mg of the resin was cleaved with 100 µL Dp solution for 2 h at 60 ℃, the
heated mixture was filtered with MeOH and 5 µL were injected into LC-MS instrument.
The exact mass was determined to be 611.3427 [MH]+.
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Figure 3.18. Scheme of dIm-Im-γ-Py-β-PAM resin. Starting from commercially
available Boc-β-pam resin: (i) wash with DCM and DMF; (ii) 60% TFA/DCM/0.5M
indole; (iii) 25% piperidine/DMF; (iv) building block; (v) 0.5M PyBOP/DMF; (vi)
DIEA; (vii) DMSO; (viii) capping with acetic anhydride.
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Polyamide 47 has been built with five consecutive programs (Table 3.6).

Building blocks

Applied programs

1 – Boc-PyOBt

Add- DIEA- 180 min- DIEA- Flows-CFN

2 - Capping

Cap- 17 min- continue- CFN

3 – Boc-γCOOH

Add- DIEA- PyBOP- 180 min- DMSO- DIEAFlows- CFN

4 – Capping

Cap- 17 min- continue- CFN

5 – dIm-ImCOOH

PreAct- 180 min- DMSO- DIEA- Flows- CFN

Table 3.6. Used Applied Program in the Synthesis of Polyamide 47.

3.2.17 Cleavage of Polyamide 47 Using Dp as a Nucleophile
After the synthesis of 47 was completed, the R.V glass was opened and gently
collected all the resin inside it using a stirring rod. The next step was placing the resin on
a filter paper inside a Buchner funnel and washed it three times with DMF, DCM, and
MeOH, then dried it under vacuum for 10 min. Compound 47 (1.66 g) was transferred
into an empty polypropylene vial, then Dp (3- dimethylamino-1-propylamine) (6 mL, 60
mmol) was added to the resin.
The resin was heated with Dp solution at 40 ℃ for 23 h using an Isotemp Fisher
Scientific. After heating, the separation of polyamide solution from the resin support was
performed on a 20 µM polyethylene frit placed inside a disposable polypropylene syringe
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by washing with MeOH. Polyamide solution was concentrated in vacuum to afford 470
mg (0.76 mmol, 41% yield) (Figure 3.19).

Figure 3.19. Cleaved Polyamide 47 Via Dp.

3.2.18 Purification of dIm-Im-γ-Py-β-Dp
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The polyamide solution was diluted with a 50:50% mixture of 1200 µL DMSO
and 1200 µL H2O/ 0.2% HCOOH, then purified by reversed-phase HPLC using a
Phenomenex Luna 250 x 30 mm, 5 μM, 100 Å, C18 (version 2) column maintained at 25
˚C. The organic phases were 0.2% formic acid in water (A) and 100 % methanol (B). The
applied gradient was 7 % B for 15 min, followed by a ramp to 90 % B over 60 min at 20
mL/min. All pooled fractions were concentrated in vacuum to remove the MeOH from
the solution.
3.2.19 Lyophilization of dIm-Im-γ-Py-β-Dp
Compound 48 was diluted with a 50:50 % mixture of ACN (5 mL), and 0.2 %/
H2O (5 mL). The samples were frozen before lyophilization using dry ice and rotating
until an even coating of frozen material results at an acute angle in the container.
The frozen sample was covered with porous Kimtech/Kimwipe paper and secured
with a rubber band. All samples were transferred into a lyophilizer vessel and connected
to a vacuum port. The frozen polyamide converted to a fluffy white powder after 38 h.
The lyophilizer vacuum was set at 300 torr within 30 minutes, and the temperature was
set at -83 ℃.
3.2.20 Characterization of dIm-Im-γ-Py-β-Dp
Analytical HPLC characterization was carried out using a Phenomenex Jupiter
Proteo (C12), 4.6 x 50 mm, 4 μ, 90 Å column maintained at 40˚C. Mobile phases
consisted of 0.1% trifluoroacetic acid in water (A) and 100 % acetonitrile (B). The
applied gradient consisted of 5% B for 0.75 min, followed by a ramp to 60% B over 6.5
min at 0.75 mL/min. The retention time was 3.16 min.
PA48 dIm-Im-γ-Py-β-Dp (HCOO-)3:
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1

H NMR (600 MHz, DMSO-d6)  = 9.77 (s, 1 H), 9.69 (br. S., 1 H), 8.33- 8.32(d,

J = 3.51 Hz, 2 H), 8.31 (s, 1 H), 7.50 (s, 1 H), 7.43 (s, 1 H), 7.096-7.093 (d, J = 1.43 Hz,
1 H), 7.06 (s, 1 H), 6.625-6.623 (d, J = 1.51 Hz, 2 H), 3.99 (s, 3 H), 3.95 (s, 3 H), 3.76 (s,
3 H), 3.35-3.32 (m, 2 H), 3.26-3.23 (m, 2 H), 3.06-3.03 (m, 2 H), 2.31-2.29 (t, J = 14.4
Hz, 2 H), 2.28-2.26 (t, J = 10.81 Hz, 2 H), 2.25-2.23 (t, J = 11.50 Hz, 2 H), 2.15 (s, 1 H),
2.08 (s, 6H), 1.81- 1.76 (m, 2 H), 1.55-1.51 (m, 2 H).
C NMR (151 MHz, DMSO-d6)  = 206.8, 170.8, 169.4, 161.6, 158.9, 156.2,

13

138.2, 135.1, 134.8, 128.1, 127.4, 123.2, 122.4, 118.1, 114.1, 56.8, 45.1, 38.5, 37.1, 36.3,
36.1, 35.8, 35.4, 33.6, 31.1, 27.2, 25.9.
HRMS (ESI) calculated for C28H41N11O5 [MH]+, 611.3294, found, 611.3427.
HPLC purity: 97%. (Figure 3.20).

Figure 3.20. HPLC Purity of dIm-Im-γ-Py-β-Dp with 
Monitored. Compoundv48, 97% purity, retention time 3.16 min.
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3.2.21 Synthesis of dIm-Py-Py-Im-Py-γ-β-Dp
Synthesis of polyamide 58 was started by heating the CSBio reaction's vessel at
35 ℃ for 10 min. After 20 min, Boc-Beta-Ala-Pam resin 49 (1.17 g, 0.26 meq/g) was
transferred to the reaction vessel.
PyBOP (benzotriazole-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate)
(17 g, 32.7 mmol) was dissolved in DMF (54 mL) and transferred to the R4 vessel. After
3 h, a solution of Boc-γCOOH 50 (0.42 g, 2 mmol) in DMF (6 mL) was stirred for 6 min
then transferred to (AA# 2). After the first sequence was completed, a solution of BocPyOBt 52 (0.73 g, 2 mmol) in DMF (6 mL) was stirred for 5 min then transferred to the
amino acid reservoir (AA# 3). After sequence 2 was completed, a dimer of Boc-PyImCOOH 54 (0.59 g, 1.64 mmol), PyBOP (0.80 g, 1.52 mmol), and N, Ndiisopropylethylamine DIEA (1mL, 5.7 mmol) in DMF (6.5 mL) were stirred for 6 min
then transferred to (AA# 4) at the last min.
The last building block was prepared by dissolving (0.38 g, 1.56 mmol) of dImPyCOOH 56 in DMF (6 mL) and stirred for 7 min; then transferred to (AA# 5) at the last
min. The sequence was completed after 5 h (Figure 3.21).
To check sequence completion, 0.1 mg of the resin was cleaved with 100 µL Dp
solution for 2 h at 60 ℃, then the heated mixture was filtered with MeOH, and 5 µL were
injected into LC-MS instrument. The exact mass was determined to be 855.4229 [MH]+.
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Figure 3.21. Caption on the next page.
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Figure 3.21. Scheme of dIm-Py-Py-Im-Py-γ-β-PAM resin. Starting from
commercially available Boc-β-pam resin: (i) wash with DCM and DMF; (ii) 60%
TFA/DCM/0.5M indole; (iii) 25% piperidine/DMF; (iv) building block; (v) 0.5M
PyBOP/DMF; (vi) DIEA; (vii) DMSO; (viii) capping with acetic anhydride.

Polyamide 57 has been built with seven consecutive programs (Table 3.7).
Building blocks

Applied programs

1 – Boc-γCOOH

Add- DIEA- PyBOP- 180 min- DMSO- DIEAFlows- CFN

2 - Capping

Cap- 17 min- continue- CFN

3 – Boc-PyOBt

Add- DIEA- 180 min- DIEA- Flows-CFN

4 – Capping

Cap- 17 min- continue- CFN

5 – Boc-Py-ImCOOH

PreAct- 180 min- DMSO- DIEA- Flows- CFN

6 - Capping

Cap- 17 min- continue- CFN

7 – dIm-PyCOOH

PreAct- 180 min- DMSO- DIEA- Flows- CFN

Table 3.7. Used Applied Program in the Synthesis of Polyamide 57.

3.2.22 Cleavage of Polyamide 57 Using Dp as a Nucleophile
After the synthesis of 57 was completed, the R.V glass was opened and gently
collected all the resin inside it using a stirring rod. The next step was placing the resin on
a filter paper inside a Buchner funnel and washed it three times with DMF, DCM, and
MeOH, then dried it under vacuum for 10 min. Compound 57 (1.69 g) was transferred
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into an empty polypropylene vial, then Dp (3- dimethylamino-1-propylamine) (7 mL,71
mmol) was added to the resin.
The resin was heated with Dp solution at 40 ℃ for 23 h using an Isotemp Fisher
Scientific. After heating, the separation of polyamide solution from the resin support was
performed on a 20 µM polyethylene frit placed inside a disposable polypropylene syringe
by washing with MeOH. Polyamide solution was concentrated in vacuum to afford 490
mg (0.57 mmol, 42% yield) (Figure 3.22).

Figure 3.22. Cleaved Polyamide 57 Via Dp.
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3.2.23 Purification of dIm-Py-Py-Im-Py-γ-β-Dp
The polyamide solution was diluted with a 50:50% mixture of 1200 µL DMSO
and 1200 µL H2O/ 0.2% HCOOH, then purified by reversed-phase HPLC using a
Phenomenex Luna 250 x 30 mm, 5 μM, 100 Å, C18 (version 2) column maintained at 25
˚C. The organic phases were 0.2% formic acid in water (A) and 100 % methanol (B). The
applied gradient was 7 % B for 15 min, followed by a ramp to 90 % B over 60 min at 20
mL/min. All pooled fractions were concentrated in vacuum to remove the MeOH from
the solution.
3.2.24 Lyophilization of dIm-Py-Py-Im-Py-γ-β-Dp
Compound 58 was diluted with a 50:50 % mixture of ACN (5 mL), and 0.2 %/
H2O (5 mL). The samples were frozen before lyophilization using dry ice and rotating
until an even coating of frozen material results at an acute angle in the container. The
frozen sample was covered with porous Kimtech/Kimwipe paper and secured with a
rubber band. All samples were transferred into a lyophilizer vessel and connected to a
vacuum port. The frozen polyamide converted to a fluffy white powder after 38 h. The
lyophilizer vacuum was set at 300 torr within 30 minutes, and the temperature was set at 83 ℃.
3.2.25 Characterization of dIm-Py-Py-Im-Py-γ-β-Dp
Analytical HPLC characterization was carried out using a Phenomenex Jupiter
Proteo (C12), 4.6 x 50 mm, 4 μ, 90 Å column maintained at 40˚C. Mobile phases
consisted of 0.1% trifluoroacetic acid in water (A) and 100 % acetonitrile (B). The
applied gradient consisted of 5% B for 0.75 min, followed by a ramp to 60% B over 6.5
min at 0.75 mL/min. The retention time was 4.29 min.
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PA58 dIm-Py-Py-Im-Py-γ-β-Dp (HCOO-)3:
1

H NMR (600 MHz, DMSO-d6)  = 10.38 (s, 3 H), 10.19 (s, 1 H), 8.29 (s, 3 H),

7.51 (s, 1 H), 7.35 (s, 1 H), 7.313- 7.311 (d, J = 1.36 Hz, 1 H), 7.275-7.273 (d, J = 1.56
Hz, 1 H), 7.19 (s, 1 H), 7.14 (s, 1 H), 7.06 (s, 1 H), 7.01 (s, 1 H), 6.62 (s, 1 H), 3.97 (s, 3
H), 3.95 (s, 3 H), 3.838 (s, 3H), 3.830 (s, 3 H), 3.78 (s, 3 H), 3.22-3.18 (m, 2 H), 3.143.11 (m, 2 H), 3.03-3.00 (m, 2 H), 2.16 (s, 6 H), 2.29-2.27 (t, J = 7.18 Hz, 2 H), 2.20-2.18
(t, J = 14.09 Hz, 2 H), 2.07-2.04 (t, J = 15.09 Hz, 2 H), 1.69-1.64 (m, 2 H), 1.53-1.49 (m,
2 H).
C NMR (151 MHz, DMSO-d6)  = 172.3, 170.7, 165.6, 161.6, 159.2, 159.1,
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156.5, 156.1, 139.2, 136.5, 134.5, 127.7, 127.1, 123.7, 123.4, 122.7, 122.3, 121.8, 121.5,
120.2, 119.5, 118.7, 106.4, 105.8, 105.1, 56.6, 45.1, 44.7, 37.1, 36.5, 35.9, 35.6, 35.4,
33.4, 26.9, 26.1.
HRMS (ESI) calculated for C40H53N15O7 [MH]+, 855.4245, found, 855.4229.
HPLC purity: 98%. (Figure 3.23).

Figure 3.23. HPLC Purity of polyamide 58 with 
Monitored. Compound 58, 97% purity, retention time 4.29 min.
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3.2.26 Synthesis of TMG-Im-β-Im-γ-Py-β-Py-β-Dp
Synthesis of polyamide 72 was started by heating the CSBio reaction's vessel at
35 ℃ for 10 min. After 20 min, Boc-Beta-Ala-Pam resin 59 (1.115 g, 0.26 meq/g) was
transferred to the reaction vessel. PyBOP (benzotriazole-1-yloxytripyrrolidinophosphonium hexafluorophosphate) (17 g, 32.7 mmol) was dissolved in
DMF (54 mL) and transferred to the R4 vessel. After 3 h, a solution of Boc-β-PyCOOH
60 (0.486 g, 1.56 mmol) in DMF (6 mL) was stirred for 6.5 min then transferred to (AA#
3). After the first sequence was done, a solution of Boc-PyOBt 62 (0.73 g, 2 mmol) in
DMF (6 mL) was stirred for 5 min then transferred to the amino acid reservoir (AA# 4).
After sequence 2 was completed, dissolved (0.42 g, 2.08 mmol) of Boc-γCOOH 64 in
DMF (6 mL) and stirred for 4 min, then transferred to (AA# 5). A dimer of Boc-βImCOOH 66 (0.487 g, 1.56 mmol), PyBOP (0.80 g, 1.52 mmol), and N, Ndiisopropylethylamine DIEA (1mL, 5.7 mmol) in DMF (6.5 mL) were stirred for 5 min
then transferred to (AA# 6) at the last min. After sequence 4 was completed, a solution of
Boc-ImCOOH 68 (0.50 g, 2.08 mmol), PyBOP (1 g, 1.9 mmol), and N, Ndiisopropylethylamine DIEA (1mL, 5.7 mmol) in DMF (6.5 mL) were stirred for 6.5
min; then transferred to (AA# 7) at the last min. To check sequence completion, 0.1 mg
of the resin was cleaved with 100 µL Dp solution for 2 h at 60 ℃, then the heated
mixture was filtered with MeOH, and 5 µL were injected into LC-MS instrument. The
exact mass was determined to be 990.5151 [MH]+. After 3 h, a solution of HATU (1[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b] pyridinium 3-oxide
hexafluorophosphate) 70 (0.92 g, 2.42 mmol) in DMF (6.5 mL) was stirred for 5 min
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then transferred to the amino acid reservoir (AA# 8) to introduce (TMG) group on the
final sequence (Figure 3.24).

Figure 3.24 Part 1
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Figure 3.24. Part 2. Scheme of TMG-Im-β-Im-γ-Py-β-Py-β-PAM resin. Starting from
commercially available Boc-β-pam resin: (i) wash with DCM and DMF; (ii) 60%
TFA/DCM/0.5M indole; (iii) 25% piperidine/DMF; (iv) building block; (v) 0.5M
PyBOP/DMF; (vi) DIEA; (vii) DMSO; (viii) capping with acetic anhydride.
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Polyamide 71 has been built with eleven consecutive programs (Table 3.8).
Building blocks

Applied programs

1 – Boc-β-PyCOOH

Add- DIEA- PyBOP- 180 min- DMSO- DIEA- Flows- CFN

2 - Capping

Cap- 17 min- continue- CFN

3 – Boc-PyOBt

Add- DIEA- 180 min- DIEA- Flows-CFN

4 – Capping

Cap- 17 min- continue- CFN

5 – Boc-γCOOH

Add- DIEA- PyBOP- 180 min- DMSO- DIEA- Flows- CFN

6 - Capping

Cap- 17 min- continue- CFN

7 – Boc-β-ImCOOH

PreAct- 180 min- DMSO- DIEA- Flows- CFN

8 - Capping

Cap- 17 min- continue- CFN

9 – Boc-ImCOOH

PreAct- 180 min- DMSO- DIEA- Flows- CFN

10- Capping

Cap- 17 min- continue- CFN

11 – HATU Solution

Add-TMG-DIEA-180 min- DMSO-DIEA-Flows-CFN

Table 3.8. Used Applied Program in the Synthesis of Polyamide 71.

3.2.27 Cleavage of Polyamide 71 Using Dp as a Nucleophile
After the synthesis of 71 was completed, the R.V glass was opened and gently
collected all the resin inside using a stirring rod. The next step was placing the resin on a
filter paper inside a Buchner funnel and washed it three times with DMF, DCM, and
MeOH, then dried it under vacuum for 9 min. Compound 71 (1.80 g) was transferred into
an empty polypropylene vial, then Dp (3- dimethylamino-1-propylamine) (8 mL, 81
mmol) was added to the resin. The resin was heated with Dp solution at 38 ℃ for 23 h
using an Isotemp Fisher Scientific. After heating, the separation of polyamide solution
from the resin support was performed on a 20 µM polyethylene frit placed inside a
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disposable polypropylene syringe by washing with MeOH. Polyamide solution was
concentrated in vacuum to afford 580 mg (0.58 mmol, 52% yield) (Figure 3.25).

Figure 3.25. Cleaved Polyamide 71 Via Dp.

3.2.28 Purification of TMG-Im-β-Im-γ-Py-β-Py-β-Dp
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The polyamide solution was diluted with a 50:50% mixture of 1300 µL DMSO
and 1300 µL H2O/ 0.2% HCOOH, then purified by reversed-phase HPLC using a
Phenomenex Luna 250 x 30 mm, 5 μM, 100 Å, C18 (version 2) column maintained at 25
˚C. The organic phases were 0.2% formic acid in water (A) and 100 % methanol (B). The
applied gradient was 2 % B for 10 min, followed by a ramp to 80 % B over 40 min at 20
mL/min. All pooled fractions were concentrated in vacuum to remove the MeOH from
the solution.
3.2.29 Lyophilization of TMG-Im-β-Im-γ-Py-β-Py-β-Dp
Compound of 72 was diluted with a 50:50 % mixture of ACN (7 mL) and 0.2 %/
H2O (7 mL). The samples were frozen before lyophilization using dry ice and rotating
until an even coating of frozen material results at an acute angle in the container. The
frozen sample was covered with porous Kimtech/Kimwipe paper secured with a rubber
band. All samples were transferred into a lyophilizer vessel and connected to a vacuum
port. The frozen polyamide converted to a yellow-orange powder after 48 h. The
lyophilizer vacuum was set at 300 torr within 30 minutes, and the temperature was set at 83 ℃.
3.2.30 Characterization of TMG-Im-β-Im-γ-Py-β-Py-β-Dp
Analytical HPLC characterization was carried out using a Phenomenex Jupiter
Proteo (C12), 4.6 x 50 mm, 4 μ, 90 Å column maintained at 40˚C. Mobile phases
consisted of 0.1% trifluoroacetic acid in water (A) and 100 % acetonitrile (B). The
applied gradient consisted of 5% B for 0.75 min, followed by a ramp to 60% B over 6.5
min at 1.2 mL/min. The retention time was 2.88 min.
PA72 TMG-Im-β-Im-γ-Py-β-Py-β-Dp (HCOO-)4:
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1

H NMR (600 MHz, DMSO-d6)  = 10.35 (s, 1 H), 9.86 (s, 2 H), 9.78 (s, 2 H),

8.32 (s, 4 H), 7.33 (s, 1 H), 7.08 (s, 2 H), 7.06 (s, 2 H), 6.97 (s, 2 H), 3.89 (s, 3 H), 3.86
(s, 3 H), 3.74 (s, 6 H), 3.48-3.45 (m, 2 H), 3.40-3.36 (m, 2 H), 3.33-3.30 (m, 2 H), 3.243.21 (m, 2 H), 3.03-3.00 (m, 2 H), 2.79 (s, 6 H), 2.57-2.55 (t, J = 12.56 Hz, 6 H), 2.312.26 (m, 2 H), 2.22-2.20 (t, J = 14.13 Hz, 2 H), 2.16 (s, 12 H), 1.77-1.72 (m, 2 H), 1.541.50 (m, 2 H).
C NMR (151 MHz, DMSO-d6)  = 170.8, 169.4, 169.1, 169.2, 168.2, 168.3,
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165.7, 165.6, 161.6, 161.6, 159.0, 158.6, 158.4, 123.2, 123.2, 122.3, 122.3, 118.4, 118.4,
117.7, 117.7, 56.5, 45.2, 44.9, 44.6, 38.5, 38.5, 37.1, 37.1, 36.5, 36.3, 35.9, 35.4, 35.4,
35.3, 35.3, 33.5, 26.8, 25.9.
HRMS (ESI) calculated for C45H68N18O8 [MH]+, 988.5470, found, 988.5511.
HPLC purity: 98%. (Figure 3.26).

Figure 3.26. HPLC Purity of polyamide 72 with  Monitored.
Compound 72, 98% purity, retention time 2.88 min.
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3.2.31 Synthesis of TMG-Py-β-Im-Py-Im-γ-Py-Py-β-Dp
Synthesis of polyamide 86 was started by heating the CSBio reaction's vessel at
℃ for 10 min. After 20 min, transferred of Boc-Beta-Ala-Pam resin 73 (1.114 g, 0.26
meq/g) was transferred to the reaction vessel. PyBOP (benzotriazole-1-yloxytripyrrolidinophosphonium hexafluorophosphate) (20 g, 38.47 mmol) was dissolved
in DMF (63 mL) and transferred to the R4 vessel. After 3 h, a solution of Boc-PyPyCOOH 74 (0.56 g, 1.56 mmol) in DMF (6 mL) was stirred for 4 min then transferred
to (AA# 3). After the first sequence was completed, a solution of Boc-γCOOH 76 (0.42
g, 2.08 mmol) in DMF (6 mL) was stirred for 3 min; then transferred to the amino acid
reservoir (AA# 4). After sequence 2 was completed, a dimer of Boc-Py-ImCOOH 78
(0.63 g, 1.73 mmol), PyBOP (0.83 g, 1.57 mmol), and N, N-diisopropylethylamine DIEA
(1mL, 5.7 mmol) in DMF (6 mL) were stirred for 7 min, then transferred to (AA# 5) at
the last min. After sequence 3 was finished, a dimer of Boc-β-ImCOOH 80 (0.58 g, 1.58
mmol), PyBOP (0.83 g, 1.57 mmol), and N, N-diisopropylethylamine DIEA (1mL, 5.7
mmol) in DMF (6.5 mL) were stirred for 8 min then transferred to (AA# 6) at the last
min. After sequence 4 was completed, a solution of Boc-PyOBt 82 (0.74 g, 2.08 mmol) in
DMF (6.5 mL) was stirred for 4 min; then transferred to (AA# 7). To check sequence
completion, 0.1 mg of the resin was cleaved with 100 µL Dp solution for 2 h at 60 ℃,
then the heated mixture was filtered with MeOH, and 5 µL were injected into LC-MS
instrument. The exact mass was determined to be 1163.5740 [MH]+. After 3 h, a solution
of HATU (1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b] pyridinium 3oxide hexafluorophosphate) 84 (1.17 g, 3 mmol) in DMF (6.5 mL) was stirred for 5 min
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then transferred to the amino acid reservoir (AA# 8) to introduce (TMG) group on the
final sequence (Figure 3.27).

Figure 3.27. Part 1
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Figure 3.27. Part 2. Caption on next
page
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Figure 3.27. Part 2. Scheme of TMG-Py-β-Im-Py-Im-γ-Py-Py-β-PAM resin. Starting from
commercially available Boc-β-pam resin: (i) wash with DCM and DMF; (ii) 60%
TFA/DCM/0.5M indole; (iii) 25% piperidine/DMF; (iv) building block; (v) 0.5M
PyBOP/DMF; (vi) DIEA; (vii) DMSO; (viii) capping with acetic anhydride.

Polyamide 85 has been built with eleven consecutive programs (Table 3.9).
Building blocks

Applied programs

1 – Boc-Py-PyCOOH

Add- DIEA- PyBOP- 180 min- DMSO- DIEA- Flows- CFN

2 - Capping

Cap- 17 min- continue- CFN

3 - Boc-γCOOH

Add- DIEA- PyBOP- 180 min- DMSO- DIEA- Flows- CFN

4 - Capping

Cap- 17 min- continue- CFN

5 - Boc-Py-ImCOOH

PreAct- 180 min- DMSO- DIEA- Flows- CFN

6 - Capping

Cap- 17 min- continue- CFN

7 - Boc-β-ImCOOH

PreAct- 180 min- DMSO- DIEA- Flows- CFN

8 - Capping

Cap- 17 min- continue- CFN

9 – Boc-PyOBt

Add- DIEA- 180 min- DIEA- Flows-CFN

10 – Capping

Cap- 17 min- continue- CFN

11 - HATU Solution

Add-TMG-DIEA-180 min- DMSO-DIEA-Flows-CFN

Table 3.9. Used Applied Program in the Synthesis of Polyamide 85.

3.2.27 Cleavage of Polyamide 85 Using Dp as a Nucleophile
After the synthesis of 85 was completed, the R.V glass was opened and gently
collected all the resin inside it using a stirring rod. The next step was placing the resin on
a filter paper inside a Buchner funnel and washed it three times with DMF, DCM, and
MeOH then dried it under vacuum for 11 min. Compound 85 (1.75 g) was transferred
into an empty polypropylene vial, then Dp (3- dimethylamino-1-propylamine) (6.5 mL,
100

66 mmol) was added to the resin. The resin was heated with Dp solution at 38 ℃ for 23 h
using an Isotemp Fisher Scientific. After heating, the separation of polyamide solution
from the resin support was performed on a 20 µM polyethylene frit placed inside a
disposable polypropylene syringe by washing with MeOH. Polyamide solution was
concentrated in vacuum to afford 510 mg (0.43 mmol, 46% yield) (Figure 3.28).

Figure 3.28. Cleaved Polyamide 85 Via Dp.
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3.2.28 Purification of TMG-Py-β-Im-Py-Im-γ-Py-Py-β-Dp
The polyamide solution was diluted with a 50:50% mixture of 1250 µL DMSO
and 1250 µL H2O/ 0.2% HCOOH, then purified by reversed-phase HPLC using a
Phenomenex Luna 250 x 30 mm, 5 μM, 100 Å, C18 (version 2) column maintained at 25
˚C. The organic phases were 0.2% formic acid in water (A) and 100 % methanol (B). The
applied gradient was 2 % B for 10 min, followed by a ramp to 80 % B over 40 min at 20
mL/min. All pooled fractions were concentrated in vacuum to remove the MeOH from
the solution.
3.2.29 Lyophilization of TMG-Py-β-Im-Py-Im-γ-Py-Py-β-Dp
Compound 86 was diluted with a 50:50 % mixture of ACN (6 mL), and 0.2 %/
H2O (6 mL). The samples were frozen before lyophilization using dry ice and rotating
until an even coating of frozen material results at an acute angle in the container. The
frozen sample was covered with porous Kimtech/Kimwipe paper and secured with a
rubber band. All samples were transferred into a lyophilizer vessel and connected to a
vacuum port. The frozen polyamide converted to a fluffy white powder after 48 h. The
lyophilizer vacuum was set at 300 torr within 30 minutes, and the temperature was set at 83 ℃.
3.2.30 Characterization of TMG-Py-β-Im-Py-Im-γ-Py-Py-β-Dp
Analytical HPLC characterization was carried out using a Phenomenex Jupiter
Proteo (C12), 4.6 x 50 mm, 4 μ, 90 Å column maintained at 40˚C. Mobile phases
consisted of 0.1% trifluoroacetic acid in water (A) and 100 % acetonitrile (B). The
applied gradient consisted of 5% B for 0.75 min, followed by a ramp to 60% B over 6.5
min at 1.2 mL/min. The retention time was 3.07 min.
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PA86 TMG-Py-β-Im-Py-Im-γ-Py-Py-β-Dp (HCCO-)4:
1

H NMR (600 MHz, DMSO-d6)  = 10.38 (s, 1 H), 10.25 (s, 2 H), 9.87 (s, 1 H), 9.83 (s, 1

H), 8.35 (s, 4 H), 7.45 (s, 2 H), 7.41 (s, 2 H), 7.35 (s, 2 H), 7.14 (s, 2 H), 7.12 (s, 4 H),
3.92 (s, 3 H), 3.90 (s, 3 H), 3.83 (s, 3 H), 3.788 (s, 3 H), 3.785 (s, 3 H), 3.76 (s, 3 H),
3.45- 3.41 (m, 4 H), 3.34-3.31 (m, 2 H), 3.28-3.24 (m, 2 H), 3.04-3.01 (m, 2 H), 2.572.55 (t, J = 6.94 Hz, 4 H), 2.30-2.27 (t, J = 7.11 Hz, 2 H), 2.11 (s, 6 H), 2.05 (s, 12 H),
1.80-1.75 (m, 2 H), 1.53-1.48 (m, 2 H).
C NMR (151 MHz, DMSO-d6)  = 206.9, 170.8, 169.5, 168.9, 168.9, 165.8, 165.7,
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161.6, 161.2, 159.1, 159.1, 158.8, 158.8, 156.1, 156.1, 136.4, 136.4, 136.4, 134.4, 134.3,
134.3, 124.8, 124.8, 123.2, 122.5, 122.5, 122.5, 118.9, 118.7, 56.2, 45.2, 44.9, 37.1, 36.7,
36.3, 36.3, 35.9, 33.5, 31.3, 31.3, 31.1, 31, 31, 31, 31, 31, 27.2, 26.1.
HRMS (ESI) calculated for C54H75N21O9 [MH]+, 1162.3143, found, 1162.5766.
HPLC purity: 97%. (Figure 3.29).

Figure 3.29. HPLC Purity of polyamide 86 with 
Monitored. Compound 86, 97% purity, retention time 3.07 min.
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3.2.31 Synthesis of dIm-Py-β-Im-γ-Py-Py-β-Py-β-Dp
Synthesis of polyamide 98 was started by heating the CSBio reaction's vessel at
35 ℃ for 10 min. After 20 min, Boc-Beta-Ala-Pam resin 87 (1.103 g, 0.25 meq/g) was
transferred to the reaction vessel. PyBOP (benzotriazole-1-yloxytripyrrolidinophosphonium hexafluorophosphate) (20 g, 38.47 mmol) was dissolved
in DMF (63 mL) and transferred to the R4 vessel. After 3 h, a solution of Boc-βPyCOOH 88 (0.486 g, 1.56 mmol) in DMF (6 mL) was stirred for 6 min then transferred
to (AA# 1).
After the first sequence was completed, a solution of Boc-Py-PyCOOH 90 (0.565
g, 1.56 mmol) in DMF (6 mL) was stirred for 5 min; then transferred to the amino acid
reservoir (AA# 2). After sequence 2 was completed, a monomer of Boc-γCOOH 92
(0.422 g, 2.08 mmol) in DMF (6 mL) was stirred for 4 min; then transferred to (AA# 3).
After sequence 3 was finished, a dimer of Boc-β-ImCOOH 94 (0.487 g, 1.56 mmol),
PyBOP (0.83 g, 1.57 mmol), and N, N-diisopropylethylamine DIEA (1mL, 5.7 mmol) in
DMF (6.5 mL) were stirred for 8 min, then transferred to (AA# 4) at the last min. After
sequence 4 was completed, a solution of dIm-PyCOOH 96 (0.387 g, 1.56 mmol), PyBOP
(0.83 g, 1.57 mmol), and N, N-diisopropylethylamine DIEA (1mL, 5.7 mmol) in DMF
(6.5 mL) were stirred for 8 min; then transferred to (AA# 5) at the last min (Figure 3.30).
To check sequence completion, 0.1 mg of the resin was cleaved with 100 µL Dp solution
for 2 h at 60 ℃, then the heated mixture was filtered with MeOH, and 5 µL were injected
into LC-MS instrument. The exact mass was determined to be 1119.5478 [MH]+.
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Figure 3.30. Part 1.
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Figure 3.30. Part 2. Scheme of dIm-Py-β-Im-γ-Py-Py-β-Py-β-PAM resin. Starting from
commercially available Boc-β-pam resin: (i) wash with DCM and DMF; (ii) 60%
TFA/DCM/0.5M indole; (iii) 25% piperidine/DMF; (iv) building block; (v) 0.5M
PyBOP/DMF; (vi) DIEA; (vii) DMSO; (viii) capping with acetic anhydride.

Polyamide 97 has been built with nine consecutive programs (Table 3.10).
Building blocks

Applied programs

1 – Boc-β-PyCOOH

Add- DIEA- PyBOP- 180 min- DMSO- DIEA- Flows- CFN

2 - Capping

Cap- 17 min- continue- CFN

3 - Boc-Py-PyCOOH

Add- DIEA- PyBOP- 180 min- DMSO- DIEA- Flows- CFN

4 - Capping

Cap- 17 min- continue- CFN

5 - Boc-γCOOH

Add- DIEA- PyBOP- 180 min- DMSO- DIEA- Flows- CFN

6 - Capping

Cap- 17 min- continue- CFN

7 - Boc-β-ImCOOH

PreAct- 180 min- DMSO- DIEA- Flows- CFN

8 - Capping

Cap- 17 min- continue- CFN

9 – dIm-PyCOOH

PreAct- 180 min- DMSO- DIEA- Flows- CFN

Table 3.10. Used Applied Program in the Synthesis of Polyamide
97.

3.2.32 Cleavage of Polyamide 97 Using Dp as a Nucleophile
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After the synthesis of 97 was completed, the R.V glass was opened and gently
collected all the resin inside it using a stirring rod. The next step was placing the resin on
a filter paper inside a Buchner funnel and washed it three times with DMF, DCM, and
MeOH then dried it under vacuum for 11 min. Compound 97 (1.91 g) was transferred
into an empty polypropylene vial, then Dp (3- dimethylamino-1-propylamine) (6 mL, 60
mmol) was added to the resin. The resin was heated with Dp solution at 40 ℃ for 23 h
using an Isotemp Fisher Scientific. After heating, the separation of polyamide solution
from the resin support was performed on a 20 µM polyethylene frit placed inside a
disposable polypropylene syringe by washing with MeOH. Polyamide solution was
concentrated in vacuum to afford 644 mg (0.57 mmol, 58% yield) (Figure 3.31).

Figure 3.31. Part 1.
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Figure 3.31. Part 2. Cleaved Polyamide 97 via Dp.

3.2.28 Purification of dIm-Py-β-Im-γ-Py-Py-β-Py-β-Dp
The polyamide solution was diluted with a 50:50% mixture of 1400 µL DMSO
and 1400 µL H2O/ 0.2% HCOOH, then purified by reversed-phase HPLC using a
Phenomenex Luna 250 x 30 mm, 5 μM, 100 Å, C18 (version 2) column maintained at 25
˚C. The organic phases were 0.2% formic acid in water (A) and 100 % methanol (B). The
applied gradient was 7 % B for 15 min, followed by a ramp to 90 % B over 60 min at 20
mL/min. All pooled fractions were concentrated in vacuum to remove the MeOH from
the solution.
3.2.29 Lyophilization of dIm-Py-β-Im-γ-Py-Py-β-Py-β-Dp
Compound 98 was diluted with a 50:50 % mixture of ACN (7 mL), and 0.2 %/
H2O (7 mL). The samples were frozen before Lyophilization using dry ice and rotating
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until an even coating of frozen material results at an acute angle in the container. The
frozen sample was covered with porous Kimtech/Kimwipe paper and secured with a
rubber band. All samples were transferred into a lyophilizer vessel and connected to a
vacuum port. The frozen polyamide converted to fluffy white powder after 38 h. The
lyophilizer vacuum was set at 300 torr within 30 minutes, and the temperature was set at 83 ℃.
3.2.30 Characterization of dIm-Py-β-Im-γ-Py-Py-β-Py-β-Dp
Analytical HPLC characterization was carried out using a Phenomenex Jupiter
Proteo (C12), 4.6 x 50 mm, 4 μ, 90 Å column maintained at 40˚C. Mobile phases
consisted of 0.1% trifluoroacetic acid in water (A) and 100 % acetonitrile (B). The
applied gradient consisted of 5% B for 0.75 min, followed by a ramp to 60% B over 6.5
min at 0.80 mL/min. The retention time was 4.40 min.
PA98 dIm-Py-β-Im-γ-Py-Py-β-Py-β-Dp (HCCO-)3:
1

H NMR (600 MHz, DMSO-d6)  = 10.31 (s, 2 H), 10.27 (s, 1 H), 8.30 (s, 2 H),

7.36 (s, 1 H), 7.33 (s, 3 H), 7.20 (s, 1 H), 7.15 (s, 1 H), 7.11-7.06 (d, J = 11.25 Hz, 1 H),
6.99 (s, 4 H), 6.93 (s, 4 H), 6.81-6.79 (d, J = 13.40 Hz, 1 H), 3.94 (s, 3 H), 3.87 (s, 3 H),
3.77 (s, 9 H), 3.74 (s, 3 H), 3.43-3.40 (m, 3 H), 3.33-3.30 (m, 2 H), 3.26-3.22 (m, 2 H),
3.04-3.00 (m, 2 H), 2.56-2.53 (t, J = 7.39 Hz, 6 H), 2.29-2.27 (t, J = 6.52 Hz, 2 H), 2.15
(s, 6 H), 1.79-1.74 (m, 2 H), 1.53-1.46 (m, 2 H).
C NMR (151 MHz, DMSO-d6)  = 170.8, 169.5, 168.9, 168.9, 168.2, 161.7,
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161.6, 161.6, 159.1, 159.8, 156.5, 156.5, 139.2, 136.3, 134.3, 134.3, 127.4, 127.4, 126.7,
126.7, 123.5, 123.5, 118.6, 118.6, 118.6, 118.6, 118.4, 118.4, 114.0, 114.0, 56.7, 44.9,
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38.5, 37.1, 37.1, 37.1, 37.1, 36.4, 36.3, 36.3, 36.3, 36.2, 36.0, 36.0, 35.9, 35.9, 33.6, 27.1,
26.0.
HRMS (ESI) calculated for C52H69N19O10 [MH]+, 1119.5478, found, 1119.5487.
HPLC purity: 98%. (Figure 3.32).

Figure 3.32. HPLC Purity of polyamide 98 with  Monitored.
Compound 98, 98% purity, retention time 4.40 min.

3.2.31 Synthesis of TMG-Im-Py-Py-Im-γ-Py-Py-Py-Py-β-Dp
Synthesis of polyamide 114 was started by heating the CSBio reaction's vessel at
35 ℃ for 10 min. After 20 min, Boc-Beta-Ala-Pam resin 99 (1.161 g, 0.27 meq/g) was
transferred to the reaction vessel. PyBOP (benzotriazole-1-yloxytripyrrolidinophosphonium hexafluorophosphate) (20 g, 38.47 mmol) was dissolved
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in DMF (63 mL) and transferred to the R4 vessel. After 3 h, a solution of Boc-PyPyCOOH 100 (0.62 g, 1.72 mmol) in DMF (6 mL) was stirred for 6 min then transferred
to (AA# 3). After the first sequence was completed, another solution of Boc-Py-PyCOOH
102 (0.62 g, 1.72 mmol) in DMF (6 mL) was stirred for 6 min then transferred to (AA#
4). After sequence 2 was completed, a solution of Boc-γCOOH 104 (0.49 g, 2.42 mmol)
in DMF (6 mL) was stirred for 4 min; then transferred to the amino acid reservoir (AA#
5). After sequence 3 was finished, a dimer of Boc-Py-ImCOOH 106 (0.66 g, 1.81 mmol),
PyBOP (0.83 g, 1.57 mmol), and N, N-diisopropylethylamine DIEA (1mL, 5.7 mmol) in
DMF (6 mL) were stirred for 7 min, then transferred to (AA# 6) at the last min. After
sequence 4 was completed, a solution of Boc-PyOBt 108 (0.74 g, 2.08 mmol) in DMF
(6.5 mL) was stirred for 5 min; then transferred to (AA# 7). After sequence 5 was
finished, a monomer of Boc-ImCOOH 110 (0.50 g, 2.08 mmol), PyBOP (1 g, 2.08
mmol), and N, N-diisopropylethylamine DIEA (1mL, 5.7 mmol) in DMF (6 mL) were
stirred for 8 min, then transferred to (AA# 8) at the last min.To check sequence
completion, 0.1 mg of the resin was cleaved with 100 µL Dp solution for 2 h at 60 ℃, the
heated mixture was filtered with MeOH, and 5 µL were injected into LC-MS instrument.
The exact mass was determined to be 1336.6329 [MH]+. All the resin was transferred
from the R.V and washed three times with DMF, DCM, and MeOH, then dried under
vacuum for 12 min and kept in the freezer. The next day, the dried resin was transferred
from the freezer to the R.V to complete the sequence. After 5 h, a solution of HATU (1[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b] pyridinium 3-oxide
hexafluorophosphate) 112 (1.22 g, 3.12 mmol) in DMF (6.7 mL) was stirred for 6 min;
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then transferred to the amino acid reservoir (AA# 9) to introduce (TMG) group on the
final sequence (Figure 3.33).

Figure 3.33. Part 1
112

Figure 3.33. Part 2
113

Figure 3.33. Part 3. Scheme of TMG-Im-Py-Py-Im-γ-Py-Py-Py-Py-β-PAM resin.
Starting from commercially available Boc-β-pam resin: (i) wash with DCM and DMF; (ii)
60% TFA/DCM/0.5M indole; (iii) 25% piperidine/DMF; (iv) building block; (v) 0.5M
PyBOP/DMF; (vi) DIEA; (vii) DMSO; (viii) capping with acetic anhydride.

Polyamide 113 has been built with eleven consecutive programs (Table 3.11).
Building blocks

Applied programs

1 – Boc-Py-PyCOOH

Add- DIEA- PyBOP- 180 min- DMSO- DIEA- Flows- CFN

2 - Capping

Cap- 17 min- continue- CFN

3 – Boc-γCOOH

Add- DIEA- PyBOP- 180 min- DMSO- DIEA- Flows- CFN

4 - Capping

Cap- 17 min- continue- CFN

5 - Boc-Py-ImCOOH

PreAct- 180 min- DMSO- DIEA- Flows- CFN

6 - Capping

Cap- 17 min- continue- CFN

7 - Boc-PyOBt

Add- DIEA- 180 min- DIEA- Flows-CFN

8 - Capping

Cap- 17 min- continue- CFN

9 – Boc-ImCOOH

PreAct- 180 min- DMSO- DIEA- Flows- CFN

10 - Capping

Cap- 17 min- continue- CFN

11 - HATU Solution

Add-TMG-DIEA-180 min- DMSO-DIEA-Flows-CFN

Table 3.11. Used Applied Program in the Synthesis of Polyamide 113.
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3.2.32 Cleavage of Polyamide 113 Using Dp as a Nucleophile
After the synthesis of 113 was completed, the R.V glass was opened and gently
collected all the resin inside it using a stirring rod. The next step was placing the resin on
a filter paper inside a Buchner funnel and washed it three times with DMF, DCM, and
MeOH then dried it under vacuum for 11 min. Compound 113 (1.71 g) was transferred
into an empty polypropylene vial, then Dp (3- dimethylamino-1-propylamine) (6 mL, 60
mmol) was added to the resin. The resin was heated with Dp solution at 38 ℃ for 23 h
using an Isotemp Fisher Scientific. After heating, the separation of polyamide solution
from the resin support was performed on a 20 µM polyethylene frit placed inside a
disposable polypropylene syringe by washing with MeOH. Polyamide solution was
concentrated in vacuum to afford 505 mg (0.38 mmol, 43% yield) (Figure 3.34).

Figure 3.34. Part 1
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Figure 3.34. Part 2. Cleaved Polyamide 113 via Dp.

3.2.28 Purification of TMG-Im-Py-Py-Im-γ-Py-Py-Py-Py-β-Dp
The polyamide solution was diluted with a 50:50% mixture of 950 µL DMSO and
950 µL H2O/ 0.2% HCOOH, then purified by reversed-phase HPLC using a Phenomenex
Luna 250 x 30 mm, 5 μM, 100 Å, C18 (version 2) column maintained at 25 ˚C. The
organic phases were 0.2% formic acid in water (A) and 100 % methanol (B). The applied
gradient was 2 % B for 10 min, followed by a ramp to 80 % B over 40 min at 20 mL/min.
All pooled fractions were concentrated in vacuum to remove the MeOH from the
solution.
3.2.29 Lyophilization of TMG-Im-Py-Py-Im-γ-Py-Py-Py-Py-β-Dp
Compound 114 was diluted with a 50:50 % mixture of ACN (5 mL), and 0.2 %/
H2O (5 mL). The samples were frozen before lyophilization using dry ice and rotating
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until an even coating of frozen material results at an acute angle in the container. The
frozen sample was covered with porous Kimtech/Kimwipe paper and secured with a
rubber band. All samples were transferred into a lyophilizer vessel and connected to a
vacuum port. The frozen polyamide converted to a fluffy yellow powder after 48 h. The
lyophilizer vacuum was set at 300 torr within 30 minutes, and the temperature was set at 83 ℃.
3.2.30 Characterization of TMG-Im-Py-Py-Im-γ-Py-Py-Py-Py-β-Dp
Analytical HPLC characterization was carried out using a Phenomenex Jupiter
Proteo (C12), 4.6 x 50 mm, 4 μ, 90 Å column maintained at 40˚C. Mobile phases
consisted of 0.1% trifluoroacetic acid in water (A) and 100 % acetonitrile (B). The
applied gradient consisted of 5% B for 0.75 min, followed by a ramp to 60% B over 6.5
min at 1.2 mL/min. The retention time was 3.57 min.
PA114 TMG-Im-Py-Py-Im-γ-Py-Py-Py-Py-β-Dp (HCCO-)4:
1

H NMR (600 MHz, DMSO-d6)  = 10.23 (s, 1 H), 10.06 (s, 5 H), 9.94 (s, 1 H),

9.90 (s, 1 H), 8.33 (s, 6 H), 7.46 (s, 1 H), 7.29 (s, 1 H), 7.26 (s, 1 H), 7.20 (s, 2 H), 7.13
(s, 6 H), 3.93 (s, 3 H), 3.91 (s, 3 H), 3.82 (s, 9 H), 3.81 (s, 3 H), 3.80 (s, 3 H), 3.77 (s, 3
H), 3.35-3.32 (m, 4 H), 3.28-3.25 (m, 2 H), 3.05-3.02 (m, 2 H), 2.79 (s, 12 H), 2.31-2.25
(m, 4 H), 2.15 (s, 6 H), 2.11 (s, 1 H), 1.81-1.76 (m, 2 H), 1.54-1.50 (m, 2 H).
C NMR (151 MHz, DMSO-d6)  = 170.9, 169.5, 161.6, 161.6, 161.6, 161.6,
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161.6, 159.2, 159.1, 159.1, 158.9, 158.9, 156.1, 156.1, 136.5, 135.7, 135.7, 134.5, 134.5,
134.5, 134.5, 134.5, 123.2, 123.2, 123.2, 123.2, 123.2, 123.1, 122.6, 122.6, 122.6, 122.6,
122.6, 122.6, 121.6, 121.6, 121.6, 121.6, 121.6, 121.6, 118.3, 105.2, 56.6, 45.1, 44.8,
38.4, 37.9, 37.0, 37.0, 36.4, 36.4, 36.4, 36.4, 36.4, 36.4, 36.3, 35.9, 33.6, 26.9, 25.1.
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HRMS (ESI) calculated for C68H91N24O12 [MH]+, 1334.6649, found, 1334.7034.
HPLC purity: 98%. (Figure 3.35).

Figure 3.35. HPLC Purity of polyamide 114 with  Monitored.
Compound 114, 98% purity, retention time 3.57 min.

3.2.31 Synthesis of Guan-Im-Py-Py-Im-γ-Py-Py-Py-Py-β-Dp
Synthesis of polyamide 131 was started by heating the CSBio reaction's vessel at
35 ℃ for 10 min. After 20 min, Boc-Beta-Ala-Pam resin 115 (1.19 g, 0.27 meq/g) was
transferred to the reaction vessel. PyBOP (benzotriazole-1-yloxytripyrrolidinophosphonium hexafluorophosphate) (20 g, 38.47 mmol) was dissolved
in DMF (63 mL) and transferred to the R4 vessel. After 3 h, a solution of Boc-PyPyCOOH 116 (0.65 g, 1.80 mmol) in DMF (6 mL) was stirred for 6 min then transferred
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to (AA# 3). After the first sequence was completed, another solution of Boc-Py-PyCOOH
118 (0.65 g, 1.80 mmol) in DMF (6 mL) was stirred for 6 min then transferred to (AA#
4). After sequence 2 was completed, a solution of Boc-γCOOH 120 (0.52 g, 2.56 mmol)
in DMF (6 mL) was stirred for 4 min; then transferred to the amino acid reservoir (AA#
5). After sequence 3 was finished, a dimer of Boc-Py-ImCOOH 122 (0.69 g, 1.89 mmol),
PyBOP (0.83 g, 1.57 mmol), and N, N-diisopropylethylamine DIEA (1mL, 5.7 mmol) in
DMF (6 mL) were stirred for 7 min, then transferred to (AA# 6) at the last min. After
sequence 4 was completed, a solution of Boc-PyOBt 124 (0.74 g, 2.08 mmol) in DMF
(6.5 mL) was stirred for 5 min; then transferred to (AA# 7). After sequence 5 was
finished, a monomer of Boc-ImCOOH 126 (0.56 g, 2.32 mmol), PyBOP (1 g, 2.08
mmol), and N, N-diisopropylethylamine DIEA (1mL, 5.7 mmol) in DMF (6 mL) were
stirred for 8 min, then transferred to (AA# 8) at the last min.To check sequence
completion, 0.1 mg of the resin was cleaved with 100 µL Dp solution for 2 h at 60 ℃,
then the heated mixture was filtered with MeOH, and 5 µL were injected into LC-MS
instrument. The exact mass was determined to be 1336.6329 [MH]+. All the resin was
transferred from the R.V. and washed three times with DMF, DCM, and MeOH, then
dried under vacuum for 12 min and kept in the freezer. The next day, the dried resin was
transferred from the freezer to the R.V to complete the sequence. After 3 h, a solution of
Bis-Boc-Pyrazolocarboxamidine 128 (1.08 g, 3.48 mmol), DIEA (1mL, 5.7 mmol) in
DMF (6 mL) were stirred for 5 min and transferred to the R.V through 10 min pause step.
The sequence was finished after 26 h. Deprotection of the (Boc)2 group on the
guanidinium group using TFA solution was the last step to introduce the Guan group on
the sequence (Figure 3.36).
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Figure 3.36. Part 1
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Figure 3.36. Part 2
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Figure 3.36. Part 3. Scheme of Guan-Im-Py-Py-Im-γ-Py-Py-Py-Py-β-PAM resin.
Starting from commercially available Boc-β-pam resin: (i) wash with DCM and DMF;
(ii) 60% TFA/DCM/0.5M indole; (iii) 25% piperidine/DMF; (iv) building block; (v)
0.5M PyBOP/DMF; (vi) DIEA; (vii) DMSO; (viii) capping with acetic anhydride.
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Polyamide 130 has been built with twelve consecutive programs (Table 3.12).
Building blocks

Applied programs

1 – Boc-Py-PyCOOH

Add- DIEA- PyBOP- 180 min- DMSO- DIEA- Flows- CFN

2 - Capping

Cap- 17 min- continue- CFN

3 – Boc-γCOOH

Add- DIEA- PyBOP- 180 min- DMSO- DIEA- Flows- CFN

4 - Capping

Cap- 17 min- continue- CFN

5 - Boc-Py-ImCOOH

PreAct- 180 min- DMSO- DIEA- Flows- CFN

6 - Capping

Cap- 17 min- continue- CFN

7 - Boc-PyOBt

Add- DIEA- 180 min- DIEA- Flows-CFN

8 - Capping

Cap- 17 min- continue- CFN

9 – Boc-ImCOOH

PreAct- 180 min- DMSO- DIEA- Flows- CFN

10 - Capping

Cap- 17 min- continue- CFN

11 – Guan Solution

1 gram- pause- 24 hrs- DMF- Flows- CFN

12 - Deprotection

DMF- DCM- TFA- DCM- Flows- CFN

Table 3.12. Applied Program Used in the Synthesis of Polyamide 130.

3.2.32 Cleavage of Polyamide 130 Using Dp as a Nucleophile
After the synthesis of 130 was completed, the R.V glass was opened and gently
collected all the resin inside it using a stirring rod. The next step was placing the resin on
a filter paper inside a Buchner funnel and washed it three times with DMF, DCM, and
MeOH then dried it under vacuum for 11 min. Compound 130 (1.69 g) was transferred
into an empty polypropylene vial, then Dp (3- dimethylamino-1-propylamine) (6 mL, 61
mmol) was added to the resin. The resin was heated with Dp solution at 45 ℃ for 11 h
using an Isotemp Fisher Scientific.
After heating, the separation of polyamide solution from the resin support was
performed on a 20 µM polyethylene frit placed inside a disposable polypropylene syringe
by washing with MeOH. Polyamide solution was concentrated in vacuum to afford 480
mg (0.38 mmol, 40% yield) (Figure 3.37).
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Figure 3.37. Cleaved Polyamide 130 via Dp.

3.2.33 Purification of Guan-Im-Py-Py-Im-γ-Py-Py-Py-Py-β-Dp
The polyamide solution was diluted with a 50:50% mixture of 750 µL DMSO and
750 µL H2O/ 0.2% HCOOH, then purified by reversed-phase HPLC using a Phenomenex
Luna 250 x 30 mm, 5 μM, 100 Å, C18 (version 2) column maintained at 25 ˚C. The
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organic phases were 0.2% formic acid in water (A) and 100 % methanol (B). The applied
gradient was 10 % B for 8 min, followed by a ramp to 70 % B over 50 min at 20 mL/min.
All pooled fractions were concentrated in vacuum to remove the MeOH from the
solution.
3.2.34 Lyophilization of Guan-Im-Py-Py-Im-γ-Py-Py-Py-Py-β-Dp
Compound 131 was diluted with a 50:50 % mixture of ACN (5 mL), and 0.2 %/
H2O (5 mL). The samples were frozen before lyophilization using dry ice and rotating
until an even coating of frozen material results at an acute angle in the container. The
frozen sample was covered with porous Kimtech/Kimwipe paper and secured with a
rubber band. All samples were transferred into a lyophilizer vessel and connected to a
vacuum port. The frozen polyamide converted to a fluffy white powder after 42 h. The
lyophilizer vacuum was set at 300 torr within 30 minutes, and the temperature was set at 83 ℃.
3.2.35 Characterization of Guan-Im-Py-Py-Im-γ-Py-Py-Py-Py-β-Dp
Analytical HPLC characterization was carried out using a Phenomenex Jupiter
Proteo (C12), 4.6 x 50 mm, 4 μ, 90 Å column maintained at 40˚C. Mobile phases
consisted of 0.1% trifluoroacetic acid in water (A) and 100 % acetonitrile (B). The
applied gradient consisted of 5% B for 0.75 min, followed by a ramp to 60% B over 6.5
min at 1.2 mL/min. The retention time was 4.19 min.
PA131 Guan-Im-Py-Py-Im-γ-Py-Py-Py-Py-β-Dp (HCOO-)4:
1

H NMR (600 MHz, DMSO-d6)  = 10.46 (s, 1 H), 10.24 (s, 5 H), 9.95 (s, 1 H), 9.90 (s, 1

H), 8.67 (br. S., 1 H), 8.34 (s, 6 H), 7.46 (s, 1 H), 7.30 (s, 1 H), 7.27 (s, 2 H), 7.20 (s, 2
H), 7.13 (s, 6 H), 6.81 (s, 2 H), 3.96 (s, 3 H), 3.91 (s, 3 H), 3.91 (s, 3 H), 3.84 (s, 3 H),
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3.83 (s, 3 H), 3.82 (s, 3 H), 3.81 (s, 3 H), 3.80 (s, 3 H), 3.77 (s, 3 H), 3.35-3.32 (m, 4 H),
3.28-3.25 (m, 2 H), 3.05-3.02 (m, 2 H), 2.31 (t, J = 6.46 Hz, 4 H), 2.12 (s, 6 H), 1.81-1.77
(m, 2 H), 1.56-1.53 (m, 2 H).
C NMR (151 MHz, DMSO-d6)  = 170.9, 169.5, 161.6, 161.6, 161.6, 161.6,
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161.6, 159.2, 159.1, 158.9, 158.9, 155.7, 155.7, 136.6, 136.5, 136.5, 134.4, 134.4, 134.4,
134.4, 134.4, 123.2, 123.2, 123.2, 123.2, 123.2, 123.1, 122.6, 122.6, 122.6, 122.6, 122.6,
121.4, 121.4, 121.4, 121.4, 121.4, 121.4, 119.8, 118.8, 105.2, 65.4, 45.0, 38.4, 37.9, 36.9,
36.9, 36.4, 36.4, 36.4, 36.4, 36.49, 36.4, 36.3, 35.9, 33.6, 26.8, 24.9.
HRMS (ESI) calculated for C59H74N24O10 [MH]+, 1278.6023, found, 1278.6227.
HPLC purity: 98%. (Figure 3.38).

Figure 3.38. HPLC Purity of polyamide 131 with  Monitored.
Compound 131, 98% purity, retention time 4.19 min.
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3.2.36 Synthesis of dIm-Py-β-Py-Py-Im-Py-Py-β-Im-β-Dp
Synthesis of polyamide 143 was started by heating the CSBio reaction's vessel at
35 ℃ for 10 min. After 20 min, Boc-Beta-Ala-Pam resin 132 (1.130 g, 0.26 meq/g) was
transferred to the reaction vessel. PyBOP (benzotriazole-1-yloxytripyrrolidinophosphonium hexafluorophosphate) (20 g, 38.47 mmol) was dissolved
in DMF (63 mL) and transferred to the R4 vessel. After 3 h, a solution of Boc-βImCOOH 133 (0.487 g, 1.56 mmol), PyBOP (0.83 g, 1.57 mmol), and N, Ndiisopropylethylamine DIEA (1mL, 5.7 mmol) in DMF (6 mL) was stirred for 7 min then
transferred to (AA# 1) at the last min. After the first sequence was completed, a dimer of
Boc-Py-PyCOOH 135 (0.565 g, 1.56 mmol) in DMF (6 mL) was stirred for 6 min, then
transferred to (AA# 2). After sequence 2 was completed, a dimer of Boc-Py-ImCOOH
137 (0.566 g, 1.56 mmol), PyBOP (0.83 g, 1.57 mmol), and N, N-diisopropylethylamine
DIEA (1mL, 5.7 mmol) in DMF (6 mL) were stirred for 6 min, then transferred to (AA#
3) at the last min. After sequence 3 was finished, a solution of Boc-β-PyCOOH 139
(0.486 g, 1.56 mmol) in DMF (6 mL) was stirred for 5 min; then transferred to (AA# 4).
The last building block in this sequence was prepared by dissolving dIm-PyCOOH 141
(0.387 g, 1.56 mmol), PyBOP (0.83 g, 1.57 mmol), and N, N-diisopropylethylamine
DIEA (1mL, 5.7 mmol) in DMF (6 mL); then the mixture stirred for 8 min and placed in
(AA# 5) at the last min (Figure 3.39). To check sequence completion, 0.1 mg of the resin
was cleaved with 100 µL Dp solution for 2 h at 60 ℃, then the heated mixture was
filtered with MeOH, and 5 µL were injected into LC-MS instrument. The exact mass was
determined to be 1279.5934 [MH]+.
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Figure 3.39. Part 1
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Figure 3.39. Part 2. Scheme of dIm-Py-β-Py-Py-Im-Py-Py-β-Im-β-PAM resin.
Starting from commercially available Boc-β-pam resin: (i) wash with DCM and DMF;
(ii) 60% TFA/DCM/0.5M indole; (iii) 25% piperidine/DMF; (iv) building block; (v)
0.5M PyBOP/DMF; (vi) DIEA; (vii) DMSO; (viii) capping with acetic anhydride.

Polyamide 142 has been built with nine consecutive programs (Table 3.13).
Building blocks

Applied programs

1 – Boc-β-ImCOOH

PreAct- 180 min- DMSO- DIEA- Flows- CFN

2 - Capping

Cap- 17 min- continue- CFN

3 – Boc-Py-PyCOOH2

Add- DIEA- PyBOP- 180 min- DMSO- DIEA- Flows- CFN

4 - Capping

Cap- 17 min- continue- CFN

5 - Boc-Py-ImCOOH

PreAct- 180 min- DMSO- DIEA- Flows- CFN

6 - Capping

Cap- 17 min- continue- CFN

7 - Boc-β-PyCOOH

Add- DIEA- PyBOP- 180 min- DMSO- DIEA- Flows- CFN

8 - Capping

Cap- 17 min- continue- CFN

9 – dIm-PyCOOH

PreAct- 180 min- DMSO- DIEA- Flows- CFN

Table 3.13. Used Applied Program in the Synthesis of Polyamide 142.

3.2.37 Cleavage of Polyamide 142 Using Dp as a Nucleophile
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After the synthesis of 142 was completed, the R.V glass was opened and gently
collected all the resin inside it using a stirring rod. The next step was placing the resin on
a filter paper inside a Buchner funnel and washed it three times with DMF, DCM, and
MeOH then dried it under vacuum for 11 min. Compound 142 was transferred into an
empty polypropylene vial, then Dp (3- dimethylamino-1-propylamine) (8 mL, 81 mmol)
was added to the resin. The resin was heated with Dp solution at 40 ℃ for 23 h using an
Isotemp Fisher Scientific. After heating, the separation of polyamide solution from the
resin support was performed on a 20 µM polyethylene frit placed inside a disposable
polypropylene syringe by washing with MeOH. Polyamide solution was concentrated in
vacuum to afford 730 mg (0.57 mmol, 64% yield) (Figure 3.40).

Figure 3.40. Cleaved Polyamide 142 Via Dp.

3.2.38 Purification of dIm-Py-β-Py-Py-Im-Py-Py-β-Im-β-Dp
130

The polyamide solution was diluted with a 50:50% mixture of 1600 µL DMSO
and 1600 µL H2O/ 0.2% HCOOH, then purified by reversed-phase HPLC using a
Phenomenex Luna 250 x 30 mm, 5 μM, 100 Å, C18 (version 2) column maintained at 25
˚C. The organic phases were 0.2% formic acid in water (A) and 100 % methanol (B). The
applied gradient was 7 % B for 15 min, followed by a ramp to 90 % B over 60 min at 20
mL/min. All pooled fractions were concentrated in vacuum to remove the MeOH from
the solution.
3.2.39 Lyophilization of dIm-Py-β-Py-Py-Im-Py-Py-β-Im-β-Dp
Compound 143 was diluted with a 50:50 % mixture of ACN (12 mL), and 0.2 %/
H2O (12 mL). The samples were frozen before lyophilization using dry ice and rotating
until an even coating of frozen material results at an acute angle in the container. The
frozen sample was covered with porous Kimtech/Kimwipe paper and secured with a
rubber band. All samples were transferred into a lyophilizer vessel and connected to a
vacuum port. The frozen polyamide converted to a fluffy white powder after 38 h. The
lyophilizer vacuum was set at 300 torr within 30 minutes, and the temperature was set at 83 ℃.
3.2.40 Characterization of dIm-Py-β-Py-Py-Im-Py-Py-β-Im-β-Dp
Analytical HPLC characterization was carried out using a Phenomenex Jupiter
Proteo (C12), 4.6 x 50 mm, 4 μ, 90 Å column maintained at 40˚C. Mobile phases
consisted of 0.1% trifluoroacetic acid in water (A) and 100 % acetonitrile (B). The
applied gradient consisted of 2% B for 2 min, followed by a ramp to 70% B over 13 min
at 0.95 mL/min. The retention time was 6.02 min.
PA143 dIm-Py-β-Py-Py-Im-Py-Py-β-Im-β-Dp (4 HCOO-):

131

1

H NMR (600 MHz, DMSO-d6)  = 10.38 (s, 1 H), 10.31 (s, 4 H), 10.20 (s, 1 H),

9.92 (s, 1 H), 9.89 (s, 1 H), 8.33 (s, 5 H), 8.04 (s, 2 H), 7.99 (s, 1 H), 7.92 (s, 1 H), 7.50
(s, 2 H), 7.21 (s, 1 H), 7.16 (s, 5 H), 7.10 (s, 1 H), 3.69 (s, 6 H), 3.94 (s, 3 H), 3.88 (s, 3
H), 3.83 (s, 3 H), 3.82 (s, 3 H), 3.80 (s, 3 H), 3.76 (s, 3 H), 3.43-3.39 (m, 8 H), 3.04-3.01
(m, 2 H), 2.54-2.52 (t, J = 5.39 Hz, 6 H), 2.12 (s, 6 H), 1.65-1.63 (m, 2 H).
C NMR (151 MHz, DMSO-d6)  = 173.7, 171.6, 171.6, 161.8, 161.8, 161.8,
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159.1, 159.1, 158.9, 158.9, 158.9, 141.8, 141.8, 141.8, 139.2, 139.2, 137.2, 137.2, 136.6,
136.6, 130.1, 130.1, 130.1, 130.1, 126.2, 126.2, 126.2, 126.2, 124.4, 124.4, 124.4, 124.4,
124.4, 121.2, 121.2, 121.2, 121.2, 121.2, 116.7, 107.5, 59.2, 47.7, 40.6, 39.6, 39.6, 39.6,
39.6, 39.6, 39.1, 38.8, 38.6, 38.3, 38.1, 38.1, 38.1, 29.5.
HRMS (ESI) calculated for C59H73N23O11 [MH]+, 1279.5863, found, 1279.5934.
HPLC purity: 98%. (Figure 3.41).

Figure 3.41. HPLC Purity of polyamide 143 with  Monitored.
Compound 143, 98% purity, retention time 6.02 min.
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3.3.41 Synthesis of dIm-Py-β-Py-Py-Py-Py-Im-γ-Py-Py-Py-Py-β-Dp
Synthesis of polyamide 159 was started by heating the CSBio reaction's vessel at
35 ℃ for 10 min. After 20 min, Boc-Beta-Ala-Pam resin 144 (1.19 g, 0.27 meq/g) was
transferred to the reaction vessel. PyBOP (benzotriazole-1-yloxytripyrrolidinophosphonium hexafluorophosphate) (25 g, 48.08 mmol) was dissolved
in DMF (78 mL) and transferred to the R4 vessel. After 3 h, a solution of Boc-PyPyCOOH 145 (0.565 g, 1.56 mmol) in DMF (6 mL) was stirred for 5 min then
transferred to (AA# 1). After the first sequence was completed, another solution of BocPy-PyCOOH 147 (0.565 g, 1.56 mmol) in DMF (6 mL) was stirred for 5 min then
transferred to (AA# 2). After sequence 2 was completed, a solution of Boc-γCOOH 149
(0.52 g, 2.56 mmol) in DMF (6 mL) was stirred for 4 min; then transferred to the amino
acid reservoir (AA# 3). After sequence 3 was finished, a dimer of Boc-Py-ImCOOH 151
(0.566 g, 1.59 mmol), PyBOP (0.83 g, 1.57 mmol), and N, N-diisopropylethylamine
DIEA (1mL, 5.7 mmol) in DMF (6 mL) were stirred for 7 min, then transferred to (AA#
4) at the last min. After sequence 4 was completed, a third dimer of Boc-Py-PyCOOH
153 (0.565 g, 1.56 mmol) in DMF (6 mL) was stirred for 5 min then transferred to (AA#
5). When sequence 5 has finished, a solution of Boc-β-PyCOOH 155 (0.486 g, 1.56
mmol) in DMF (6 mL) was stirred for 5 min; then transferred to (AA# 6).
The last building block in this sequence was prepared by dissolving dImPyCOOH 157 (0.45 g, 1.84 mmol), PyBOP (0.83 g, 1.57 mmol), and N, Ndiisopropylethylamine DIEA (1mL, 5.7 mmol) in DMF (6 mL); then the mixture stirred
for 8 min and placed in (AA# 7) at the last min (Figure 3.42). To check sequence
completion, 0.1 mg of the resin was cleaved with 100 µL Dp solution for 2 h at 60 ℃,
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then the heated mixture was filtered with MeOH, and 5 µL were injected into LC-MS
instrument. The exact mass was determined to be 1658.7552 [MH]+.

Figure 3.42. Part 1
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Figure 3.42. Part 2
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Figure 3.42. Part 3. Scheme of dIm-Py-β-Py-Py-Py-Py-Im-γ-Py-Py-Py-Py-β -PAM
resin. Starting from commercially available Boc-β-pam resin: (i) wash with DCM and
DMF; (ii) 60% TFA/DCM/0.5M indole; (iii) 25% piperidine/DMF; (iv) building block;
(v) 0.5M PyBOP/DMF; (vi) DIEA; (vii) DMSO; (viii) capping with acetic anhydride.

Polyamide 158 has been built with nine consecutive programs (Table 3.14).
Building blocks

Applied programs

1 – Boc-Py-PyCOOH3

Add- DIEA- PyBOP- 180 min- DMSO- DIEA- Flows- CFN

2 - Capping

Cap- 17 min- continue- CFN

3 – Boc-γCOOH

Add- DIEA- PyBOP- 180 min- DMSO- DIEA- Flows- CFN

4 - Capping

Cap- 17 min- continue- CFN

5 - Boc-Py-ImCOOH

PreAct- 180 min- DMSO- DIEA- Flows- CFN

6 - Capping

Cap- 17 min- continue- CFN

7 - Boc-β-PyCOOH

Add- DIEA- PyBOP- 180 min- DMSO- DIEA- Flows- CFN

8 - Capping

Cap- 17 min- continue- CFN

9 – dIm-PyCOOH

PreAct- 180 min- DMSO- DIEA- Flows- CFN

Table 3.14. Used Applied Program in the Synthesis of Polyamide 158.
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3.2.42 Cleavage of Polyamide 158 Using Dp as a Nucleophile
After the synthesis of 158 was completed, the R.V glass was opened and gently
collected all the resin inside it using a stirring rod. The next step was placing the resin on
a filter paper inside a Buchner funnel and washed it three times with DMF, DCM, and
MeOH then dried it under vacuum for 11 min. Compound 158 (1.86 g) was transferred
into an empty polypropylene vial, then Dp (3- dimethylamino-1-propylamine) (8 mL, 81
mmol) was added to the resin. The resin was heated with Dp solution under 40 ℃ for 23
h using an Isotemp Fisher Scientific. After heating, the separation of polyamide solution
from the resin support was performed on a 20 µM polyethylene frit placed inside a
disposable polypropylene syringe by washing with MeOH. Polyamide solution was
concentrated in vacuum to afford 670 mg (0.40 mmol, 56% yield) (Figure 3.43).

Figure 3.43. Cleaved Polyamide 159 via Dp.
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3.2.43 Purification of dIm-Py-β-Py-Py-Py-Py-Im-γ-Py-Py-Py-Py-β-Dp
The polyamide solution was diluted with a 50:50% mixture of 1250 µL DMSO
and 1250 µL H2O/ 0.2% HCOOH, then purified by reversed-phase HPLC using a
Phenomenex Luna 250 x 30 mm, 5 μM, 100 Å, C18 (version 2) column maintained at 25
˚C. The organic phases were 0.2% formic acid in water (A) and 100 % methanol (B). The
applied gradient was 7 % B for 15 min, followed by a ramp to 90 % B over 60 min at 20
mL/min. All pooled fractions were concentrated in vacuum to remove the MeOH from
the solution.
3.2.44 Lyophilization of dIm-Py-β-Py-Py-Py-Py-Im-γ-Py-Py-Py-Py-β-Dp
Compound 159 was diluted with a 50:50% mixture of ACN (6 mL), and 0.2 %/
H2O (6 mL). The samples were frozen before lyophilization using dry ice and rotating
until an even coating of frozen material results at an acute angle in the container. The
frozen sample was covered with porous Kimtech/Kimwipe paper and secured with a
rubber band. All samples were transferred into a lyophilizer vessel and connected to a
vacuum port. The frozen polyamide converted to a fluffy white powder after 38 h. The
lyophilizer vacuum was set at 300 torr within 30 minutes, and the temperature was set at 83 ℃.
3.2.45 Characterization of dIm-Py-β-Py-Py-Py-Py-Im-γ-Py-Py-Py-Py-β-Dp
Analytical HPLC characterization was carried out using a Phenomenex Jupiter
Proteo (C12), 4.6 x 50 mm, 4 μ, 90 Å column maintained at 40˚C. Mobile phases
consisted of 0.1% trifluoroacetic acid in water (A) and 100 % acetonitrile (B). The
applied gradient consisted of 2% B for 2 min, followed by a ramp to 70% B over 13 min
at 0.95 mL/min. The retention time was 6.067 min.
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PA159 dIm-Py-β-Py-Py-Py-Py-Im-γ-Py-Py-Py-Py-β-Dp (HCOO-)3:
1

H NMR (600 MHz, DMSO-d6)  = 10.23 (s, 1 H), 10.22 (s, 7 H), 9.90 (s, 2 H),

9.84 (s, 1 H), 8.32 (s, 9 H), 7.46 (s, 2 H), 7.33 (s, 1 H), 7.30 (s, 1 H), 7.20 (s, 9 H), 7.16
(s, 1 H), 7.13 (s, 1 H), 6.99 (s, 1 H), 3.94 (s, 3 H), 3.91 (s, 3 H), 3.83 (s, 15 H), 3.81 (s, 3
H), 3.80 (s, 3 H), 3.78 (s, 3 H), 3.77 (s, 3 H), 3.44-3.41 (m, 4 H), 3.35-3.32 (m, 2 H),
3.29-3.25 (m, 2 H), 3.05-3.02 (m, 2 H), 2.51-2.49 (t, J = 6.86 Hz, 4 H), 2.31-2.25 (m, 2
H), 2.15 (s, 6 H), 1.81-1.77 (m, 2 H), 1.55-1.50 (m, 2 H).
C NMR (151 MHz, DMSO-d6)  = 170.9, 169.5, 168.3, 165.8, 165.8, 165.8,
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165.8, 165.8, 165.8, 165.8, 161.7, 161.7, 158.9, 158.9, 156.1, 156.1, 139.2, 136.5, 134.4,
134.4, 123.2, 123.2, 123.2, 123.2, 123.2, 123.2, 123.2, 122.6, 122.6, 122.6, 122.6, 122.6,
122.6, 122.6, 119.3, 119.3, 119.3, 119.3, 119.3, 119.3, 119.3, 119.3, 119.3, 119.0, 119.0,
119.0, 119.0, 119.0, 119.0, 119.1, 119.1, 119.1, 118.1, 118.1, 105.5, 56.6, 45.1, 37.5,
37.1, 36.6, 36.6, 36.6, 36.6, 36.6, 36.6, 36.6, 36.6, 36.6, 35.9, 35.9, 35.4, 35.4, 33.6, 27.1,
26.1.
HRMS (ESI) calculated for C79H94N28O14 [MH]+, 1658.7508, found, 1658.7552.
HPLC purity: 98%. (Figure 3.44).

Figure 3.44. Part 1.
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Figure 3.44. Part 2. HPLC Purity of polyamide 159 with 
Monitored. Compound 159, 98% purity, retention time 6.067
min.

3.2.46 Uptake Experiments
The following data has been obtained from Georgia State University (Ming's lab)
regarding the polyamide’s uptake experiment via HeLa cells.
HeLa cells were grown in a T-flask using Dulbecco's Modified Eagle Medium
(DMEM) containing Penicillin and Streptomycin and 10% Fetal Bovine Serum (FBS).
The old medium was vacuum-removed to split the cells, then the cells were washed with
phosphate-buffered saline solution (PBS, pH range 7.3-7.5), and then trypsin solution
was added to detach the cells. After a 3 min incubation at 37 °C with 5.0% CO2, the Tflask was smacked by hand to ensure that cells were detached and separated from each
other. Fresh DMEM ++PS 10% FBS was added to the cells, at which time a particular
portion of cells was split. Cells were split to keep them alive, and a portion of the T-flask
living cells was used to create 12-well plates for plaque assays.
The newly made plates were incubated at 37 °C, with 5.0% CO2, for 24 h before
infection. For plaque assays, the old media was vacuum-removed from each well after a
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24-hour incubation period. Each well was washed with 500 μL of Dulbecco's phosphatebuffered saline solution (DPBS, pH range 7.0-7.3). After washing, the cells were infected
with the fluorescent-tagged VSV-mph, serially diluted (10-1 to 10-6) in 500 μL DMEM
++PS without FBS. After a 1-hour incubation period, the excess media was vacuumremoved from each well, washed with 500 μL of DPBS, and 700 μL agarose gel was
applied to set the cells before a 48-hour incubation at 37 °C, with 5.0% CO2. After a 48hour incubation, the gel was removed from each well, and a 1% crystal violet stain was
applied for 15 minutes before removal. The plates were allowed to dry before taking
photographs of the plates.
Two types of studies were performed to test the antiviral activities of synthetic
polyamides. First, the compounds were screened by carrying out plaque assays in the
presence of compounds and DMSO control. After that, 100 μL of compound solutions at
concentrations of 1 mM, 0.5 mM, and 0.25 mM, or DMSO control, respectively, was
added with 600 μL agarose gel during plaque assays. To determine EC90, virus infection
was carried out by adding 100 μL of compound solutions at concentrations of 1 mM, 0.1
mM, and 0.01 mM, or DMSO control, with 500 μL of DMEM ++PS without FBS. After
24 h, samples were collected and analyzed by plaque assays.
3.3 Results and Discussion
3.3.1 Cellular Uptake in HeLa Cells
Our collaborator, Professor Ming Luo, performed two types of
studies at Georgia State University to test the synthetic polyamides' antiviral activities
against the VSV. The first study was screening the polyamides 35, 114, and 131 by
plaque assays experiment (Figure 3.45). Three different concentrations of polyamide
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solutions in 1% dimethyl sulfoxide were used in this experiment. All polyamides did not
show any antiviral activity against VSV at 0.5 µM and 0.25 µM concentrations,
respectively.
At 1 µM concentration, both polyamides 114 and 131 did not inhibit VSV
infection (HeLa cells have been killed by VSV infection). Simultaneously, the number of
plaques was relatively reduced in the presence of polyamide 35 at this concentration.

Figure 3.45. A plaque Assays. An initial screen of three polyamide compounds
at concentrations of 1 µM, 0.5 µM, and 0.25 µM alongside a control at the same
concentrations. The compound names were labeled for each well.

In the second study, virus growth was carried out in the presence of 15 µM of
eight polyamides (Figure 3.46). Short and long sequences of Polyamides 35, 98, 114,
159, 58, 86, 143, and 72, respectively, have been used in this experiment to determine the
EC90. They observed that none of the polyamides reduced the PFU by more than one log
than the DMSO control, except for polyamide 35 (which might be an error). To ensure
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whether polyamide 35 was active or not, they repeated the screening experiment, but its
antiviral activity against VSV was limited.

Figure 3.46. A Plaque Assays. DMSO was used as the solvent negative control. The
log10 values for each compound were presented in the vertical axis, and the compound
ID was marked in the horizontal axis. The plaque assay was carried out in the presence
of 15 µM of eight polyamides.

In the previous chapter, we did mention that our lab mates have sent six different
polyamide compounds for testing against VSV at Georgia State University. Only
UMSL1011 among six compounds has shown acceptable activity against VSV. When
130 µM concentration of polyamide solutions in 1% dimethyl sulfoxide (DMSO) were
added to the HeLa cells, only UMSL1011 has protected the HeLa cells from VSV
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infection. In contrast, other polyamides did not inhibit VSV infection (Figure 3.47).20
The result adapted from polyamides screening can show the possible weak uptake of
some polyamides by HeLa cells. None of the polyamide compounds except UMSL1011
showed any cellular uptake by HeLa cells.

Figure 3.47. VSV Plaque Assays. An initial screen of six polyamide
compounds (20 _g/ml) was performed.ASM authorizes an advanced degree
candidate to republish the requested material in his /her doctoral thesis or
dissertation.

This fact, alongside the weak cellular uptaking for our synthetic polyamides, has
encouraged us to investigate HeLa or other cells' cellular uptake.31-32 Several researchers
have elucidated the relationship between polyamide structure and cell permeability by
studying cellular uptake. Two prominent groups came up with two facts; first, the Nmethylimidazole position and β-alanine content might affect cellular accessibility;
second, the polyamide uptake is cell-line dependent.32-33 Shigeki Nishijima and his team
reported a study regarding the correlation between molecular size and uptake.34 The
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outcomes of this study have shown no dependency on polyamide length was observed.34
Moreover, the amine groups at the end of synthetic polyamides might be responsible for
their accumulation in cytoplasmic vesicles in mammalian cells.35 The uptake studies have
been undertaken by Peter Dervan to prove nuclear localization of DNA-binding
polyamides in the vascular endothelial growth factor (VEGF) enhancer.36 This study's
outcomes have shown that three polyamides exhibited poor nuclear localization in HeLa
cells due to the presence of β-alanine residue at the C-terminus and non-optimal linker.36
In 2016, one of our graduate lab mates, Maria Scuderi, studied the effect of
tetramethylguanidinium (TMG) and guanidinium (Guan) groups on polyamide's cellular
uptake in HPV-infected keratinocytes.37 The polyamides uptake was examined in W12E
cells in the presence of 2.5 µM concentration of PA for 24 h. Furthermore, she
investigated PA uptake in keratinocytes after 2 h incubation at 37 ℃ and 4 ℃ to evaluate
whether the PAs are transported inside the cells by passive uptake or an energydependent process. Despite the antiviral assays for these polyamides on HPV cells have
shown their ability to reduce the viral DNA load, a strong decrease in uptake for all three
polyamides was observed in W12E cells at low temperature, from which an active uptake
mechanism can be inferred. Furthermore, no uptake was observed for UMSL1011 at
either temperature, consistent with its lack of anti-HPV activity.37-38 Therefore, the need
to try different line cells instead of HeLa cells for optimizing uptake of our synthetic
polyamides was necessary. Recently, NIH has approved testing of 12 polyamides in
primary assays against RSV and 2 polyamides in primary assays against EBOV.
3.3.2 Guan, TMG, and NF- Substituted Pyrrole-Imidazole Polyamides
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The substitution with tetramethylguanidine (TMG), guanidinium (Guan), and Nformyl amine (NF) at the polyamide N-terminus can positively affect antiviral activity
against Human Papillomavirus (HPV).8,38 The TMG motif can improve the anti-HPV
activity against HPV18, while the Guan motif has been more efficient against HPV16 and
18.37 Furthermore, the substitution of these motifs at N-terminus polyamides has shown a
remarkable solubility in H2O without the aid of solubilizing agents.37
Therefore, we have found the application of these motifs is noteworthy to try
them against VSV. Substitution of these motifs at N-terminus on pyrrole or imidazole
rings might enhance the electrostatic interaction between polyamide and RNA molecule
since the RNA molecule is highly negatively charged with many sites for H-bonding. The
Guan motif has a remarkable structure since it contains two amine groups with one imine
group, which might form strong hydrogen bonding with either RNA or protein structure.
In contrast, the N-formyl group contains a high reactive carbonyl group because
of the lack of alkyl groups, facilitating nucleophilic attack. Moreover, these positive and
neutral motifs might improve PAs' stability by facilitating the PA-viral RNA binding.
Similarly, substituted N-terminal cationic or H-bonding groups increase the binding
affinity between PAs and DNA molecules.39 All N-terminal groups were added to the last
building blocks by replacing the protecting group with one of the chosen moieties.
3.3.3 Polyamides Synthesis and Characterization
Boc solid-phase methods have been used in synthesizing several short and long
polyamide sequences, as we described earlier in this chapter. HATU was the final
building block used to incorporate the TMG group onto either NH2-Im or NH2-Py
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moieties for PAs11, 72, 86, and 114. PA22 and PA131 were synthesized by reaction with
Bis-Boc-Pyrazolocarboxamidine and DIEA for 24 h, followed by TFA treatment to
remove the Boc groups from the final sequences, then produced Guan groups on both
pyrrole and imidazole moieties. PA35 was synthesized by treatment with acetic, formic
anhydride solution, and DIEA for 5 h to introduce the N-formyl neutral group on the
pyrrole moiety.
PAs48, 58, 98, 143, and 159 were synthesized by adding various building blocks
to the Boc-β-alanine PAM resin frequently up to the end of every sequence with Im
group (4-amino-N-methyl imidazole-2-carboxamide). All synthetic polyamides were
cleaved in different temperatures using dimethylaminopropylamine (Dp) as a nucleophile
to match the C-terminus group of UMSL1011. The synthetic polyamides have been
purified using reverse-phase HPLC and characterized with 1H and 13C NMR, then HR
mass spectrometry.
TMG-Substituted Pyrrole-Imidazole Polyamides
PA11 is the first sequence in our project built to mimic the crystal structure of
UMSL1011 except adding a TMG motif on the pyrrole moiety to increase the interaction
by hydrogen bonds with genomic RNA. We were changing the chain’s order or
composition by replacing one or two building blocks in the designed compound to
optimize the activity against VSV. PA72 and PA86 were built with new building blocks
such as Boc-β-ImCOOH and Boc-β-PyCOOH, while eight building blocks were used in
PA114.
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Cleavage of all polyamides from the PAM resin was successful and reliable.
Various temperatures at different times have been applied to each polyamide to avoid any
decomposition of polyamide. We have noticed that cleavage of PA11, 72, 86, and 114 at
38 ℃ for 23 h led to good results (Table 3.15). We obtained lower yields for all
polyamides when 60 ℃ for 11 h were applied. In contrast, higher yields for all
polyamides were observed when they cleaved at 38 ℃ for 23 h. we have tried other
temperatures at 32 ℃ and 50 ℃ at different times, but the yields were low.
polyamide

Applied

Time of

Yield %

temperature ℃

heating h

PA11

PA72

PA86

PA114

11, 72, 86, 114

32

8

23

30

28

24

11, 72, 86, 114

38

23

39

52

46

43

11, 72, 86, 114

50

12

32

40

37

34

11, 72, 86, 114

60

11

19

28

25

21

Table 3.15. Cleavage of PAs11, 72, 86, and 114 under Different
Temperature and Time. Cleaving under 38 ℃ for 23 h has offered good yield.

On the other hand, PA72 has obtained a higher yield than other polyamides at the
same temperatures and times. The presence of both β-Im and β-Py moieties in PA72
might lead to a higher yield quantity because of the amine group's strong nucleophilicity
on the β-alanine motif. The absence of β-Py motif and the presence of only a single β-Im
motif in PA86 might lead to a lower yield than PA72. These polyamides' purification was
another challenge after synthesis because of impurities and the possible hydrogen
interaction between the TMG and Dp groups. Therefore, we applied several gradients to
optimize their purification and remove all impurities (Table 3.16).
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Polyamide

B % (Methanol)

Retention time

Flow rate

R. T

mL/min

Purity %

11, 72, 86, 114

25

18

30

38

11, 72, 86, 114

15

22

25

50

11, 72, 86, 114

2

33

20

73

11, 72, 86, 114

8

27

16

62

Table 3.16. Purification of Polyamides Via Reversed-Phase HPLC.

We observed that an applied gradient, starting from 2% methanol for 10 min,
followed by ramp-up to 80% over 40 min, with flow rate 20 mL/min, led to good purity.
In contrast, lower purity was obtained by starting from 25% of methanol over 40 min
with a flow rate of 30 mL/min.
Guan- substituted Pyrrole-Imidazole Polyamides
The Guan motif has been substituted successfully on PA22 and PA131 after
deprotection of the Boc group from the final moiety. PA22 was built to match the crystal
structure of UMSL1011 except with added Guan motif on the N-terminal pyrrole ring,
while in PA131, we elongated the chain by linking eight building blocks together to
maintain the functional building blocks of UMSL1011. Cleavage of both polyamides
from PAM resin was successfully applied using the nucleophile Dp.
Several temperatures were applied to each polyamide to avoid polyamide
degradation. We have observed that cleavage of PA22 and PA131 at 45 ℃ for 11 h led to
convenient yields (Table 3.17).
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Applied temperature ℃

polyamide

Time of heating h

Yield %
PA22

PA131

22, 131

72

3

18

20

22, 131

60

4

25

29

22, 131

45

11

38

40

22, 131

40

15

33

37

Table 3.17. Cleavage of PAs22, and 133 under Different Temperatures and
Times. Cleaving under 45 ℃ for 11 h has offered good yield.

We obtained lower yields for both polyamides when 72 ℃ for 3 h were applied.
In contrast, higher yields for both polyamides were observed when they cleaved at 45 ℃
for 11 h. We have tried other temperatures at 40 ℃ and 60 ℃ at different times, but the
yields still not convenient. Moreover, PA131 was having a higher yield than PA22 at all
temperatures and times, perhaps because it contained more building blocks. On the other
hand, we tried many gradients through purification of both polyamides by prep HPLC
(Table 3.18).
Polyamide B % (Methanol) Retention time

Flow rate

Purity

R.T

mL/min

%

11, 131

23

20

28

40

11, 131

18

25

26

48

11, 131

10

35

20

68

11, 131

5

37

18

57

Table 3.18. Purification of Polyamides Via Reversed-Phase HPLC.
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We observed that applied gradient starting from 10% methanol for 8 min,
followed a ramp up to 70% over 50 min with flow rate 20 mL/min, led to good purity. In
contrast, the lower purity has obtained by starting from 23% of methanol over 50 min
with a flow rate of 28 mL/min.
NF- substituted Pyrrole-Imidazole Polyamides
The N-formyl amide motif was obtained by reaction the formic acid with acetic
anhydride. First, we cooled the mixture at -10 ℃, then reflux under 60 ℃ for 1.30 h, but
a lower yield was obtained. We decided to lower the reaction conditions by cooling at -5
℃ and refluxing for 1 h under 50 ℃, and a higher yield of acetic, formic anhydride was
obtained. PA35 was built by combined three building blocks to mimic the active structure
of UMSL1011 except substituting the NF motif on the pyrrole ring. Cleavage of PA35
from PAM resin was fulfilled by heating with Dp solution. We have applied many
temperatures at different times to maintain the stability of polyamide (Table 3.19). We
obtained a lower yield of 35 when 60 ℃ for 4 h was applied. In contrast, a higher yield
was observed when it cleaved at 43 ℃ for 13 h. we have tried other temperatures at 38 ℃
and 55 ℃ at different times, but the yields still inconvenient.
polyamide

Applied temperature ℃

Time of heating h

Yield %

35

60

4

28

35

55

9

32

35

43

13

43

35

38

15

38

Table 3.19. Cleavage of PA35 under Different Temperatures and Times. Cleaving
under 43 ℃ for 13 h has offered good yield.
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On the other hand, we tried many gradients through purification of PA35 by prep
HPLC (Table 3.20). We observed that applied gradient starting from 4% methanol for
12min, followed a ramp up to 60% over 45 min with flow rate 20 mL/min, led to good
purity.
Polyamide

B % (Methanol)

Retention time R.T

Flow rate mL/min Purity %

35

2

14

30

66

35

10

18

22

55

35

4

26

20

72

35

8

37

15

62

Table 3.20. Purification of PA35 via Reversed-Phase HPLC.

In contrast, the lower purity was obtained by starting from 10% of methanol over 45 min
with a flow rate of 22 mL/min.
dIm- Motif- Pyrrole-Imidazole Polyamides
Polyamides 48, 58, 98, 143, and 159 were synthesized to have imidazole moiety
as an N-terminal group. A dimer of d-Im-ImCOOH was prepared in solution phase to use
later on in synthesizing PA48. These polyamides were synthesized in different building
blocks than UMSL1011 except PA159, which was built to match UMSL1011 in the
middle of the sequence. A building block such as 1-methylimidazole-4-carboxylic acid
(dIm) has shown excellent binding affinity into the DNA-minor groove.1
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Therefore, changing polyamide’s composition was necessary to investigate the
interaction between polyamide and genomic RNA into the nucleocapsid. All polyamides
were cleaved successfully from the PAM resin by heating with Dp solution at different
temperatures (Table 3.21).
polyamide

48, 58, 98,

Applied

Time of

Yield %

temperature ℃

heating h

PA48

PA58 PA98 PA143 PA159

60

5

26

26

30

33

29

50

15

29

30

34

38

33

40

23

41

42

58

64

56

30

18

34

35

49

56

45

143, 159
48, 58, 98,
143, 159
48, 58, 98,
143, 159
48, 58, 98,
143, 159

Table 3.21. Cleavage of PAs48, 58, 98, 143, and 159 under Different
Temperatures and Times. Cleaving under 40℃ for 23 h has offered good yield.

We obtained lower yields for all polyamides when 60 ℃ for 5 h were applied. In
contrast, higher yields for all polyamides were observed when they cleaved at 40 ℃ for
23 h. we have tried other temperatures at 30 ℃ and 50 ℃ at different times, but the
yields still inconvenient. PA98 and PA143 were obtained in higher yields than others at
all temperatures and times applied. The reason again might belong to the presence of both
β-Im and β-Py moieties in their structures. PA159 compared to PA48 and PA58 had a
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better yield because it was built with extra building blocks. On the other hand, different
gradient programs were used to purify these polyamides (Table 3.22).
Polyamide

B % (Methanol)

Retention time RT

Flow rate mL/min Purity %

48, 58, 98,

25

21

24

45

15

37

10

54

7

29

20

74

3

34

15

68

143, 159
48, 58, 98,
143, 159
48, 58, 98,
143, 159
48, 58, 98,
143, 159

Table 3.22. Purification of Polyamides Via Reversed-Phase HPLC.

We observed that applied gradient starting from 7% methanol for 15 min,
followed a ramp up to 90% over 60 min with flow rate 20 mL/min, led to a higher purity.
In contrast, the lower purity has obtained by starting from 25% of methanol over 90 min
with a flow rate of 24 mL/min.
3.4 conclusion
In summary, twelve polyamides have been built on an insoluble support resin
using a CSBio peptide synthesizer. PAs11, 72, 86, and 114 were synthesized to have
tetramethylguanidine (TMG) group as N-terminal group on either pyrrole or imidazole
moieties. HATU was used to incorporate the TMG on the final building blocks in the
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presence of DIEA for 5 h. PAs 22 and 131 were synthesized to have the guanidinium
(Guan) motif on both pyrrole and imidazole rings. The Guan motif was obtained by
treatment of the polyamide with Bis-Boc-Pyrazolocarboxamidine in the presence of
DIEA for 24 h, followed by TFA treatment to remove the Boc group at the end. PA35
was synthesized to possess the N-formyl amine (NF) group on pyrrole moiety. The NF
group was obtained by reaction formic acid with acetic anhydride in cooling and heating
media. PAs48, 58, 98, 143, and 159 were synthesized by linking different building blocks
by amide bonds to final combined with dIm moiety. PAs11, 22, and 35, in particular,
were synthesized to match the truncated green portion of UMSL1011 with a significant
modification by adding N-terminal substitutions on Pyrrole moieties, while other
polyamides built-in short and long chains with maintaining the functional building blocks
against VSV to some extent in their structures. Compound dIm-ImCOOH 40 was
prepared successfully in our lab with no need to use column chromatography.
The synthetic polyamides were sent for cell culture at Georgia State University to
test them against VSV by incubating with HeLa cells. Surprisingly, none of the
polyamides have shown any antiviral activity against VSV in a plaque assays experiment.
Another study was carried out in the presence of 15 µM of all polyamides to determine
the potency of polyamides (EC90). Interestingly, negligible uptake for PA35 was
observed, which might be an error, while None of the compounds reduced the PFU by
more than one log compared to the DMSO control. According to these studies, something
likely to belong to uptake has reduced polyamide's antiviral activity against VSV. One
possibility is that HeLa cells' weak uptake of certain polyamide compounds has occurred
through the incubation. It might be the presence of the β-alanine residue at the C-

155

terminus, and a non-optimal gamma linker may affect HeLa cells uptake.36 However, the
polyamide uptake studies by HeLa cells still under investigation. On the other hand, the
polyamides contain Guan, TMG, and NF groups were more challenging in the synthesis
and purification than dIm-polyamides. We can conclude that because the Dp is a strong
nucleophile and may attack these N-terminal groups' electrophilic sites, causing failure of
synthesis. Therefore, cleavage and purification of these polyamides under mild conditions
were necessary to keep polyamide stability.
We have optimized the yield by applying several temperatures with different
heating times. We found the cleavage of PAs11, 72, 86, and 114 from PAM resin at 38
℃ for 23 h has led to a good yield. In contrast, high purity was obtained using reversedphase HPLC when 2% B for 10 min, followed a ramp up to 80% over 40 min has applied
for these polyamides. Overall, the five polyamides (48, 58, 98, 143, and 159) have shown
noteworthy high yields at cleavage from PAM resin under 40 ℃ for 23 h. Furthermore,
optimizing the purification of these polyamides has shown high purity at a gradient of 7%
B for 15 min, followed by ramp-up to 90% during 60 min time analysis. Simultaneously,
PA22 and PA131 were obtained in high yields when PAM resin's cleavage has occurred
at 45 ℃ for 11 h. Whereas high purity for both polyamides was observed at a gradient of
10% methanol for 8 min, followed by ramp-up to 70% B over 50 min. The cleavage of
PA35 using the Dp nucleophile was challenging to some extent, and we found the
cleavage at 43 ℃ for 13 h has led to the convenient result. Moreover, purification of
PA35 from all impurities by HPLC was starting at 4% B for 12 min, then ramp-up to
60% over 45 min. Furthermore, it is worthwhile to mention that the presence of both βIm and β-Py building blocks in polyamide’s structure has led to higher yield quantities
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compared to other polyamides because of the amine group's strong nucleophilicity on the
β-alanine motif.
It would be of interest in the future to optimize the structure of polyamide by
substituting some functional groups on either β-alanine or γ-turn to enforce binding with
DNA and RNA structures and optimize cellular uptake.
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